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SUMMARY 
State of the art: PD (Parkinson’s disease) is the second most common neurodegenerative 
disease affecting 4 million people worldwide. It is characterized by loss of pigmented 
neurons in the SNpc (substantia nigra pars compacta) and presence of cytoplasmic 
inclusion bodies (called Lewy bodies). In particular, the loss of dopaminergic neurons is 
responsible for both depletion of dopamine in the caudate putamen and motor 
dysfunction.  
Although the majority of cases are sporadic, mutations in the leucine-rich repeat kinase 2 
(LRRK2) gene (PARK8; OMIM #609007) are linked to late-onset autosomal dominant PD, 
accounting for up to 6-7% of familial PD cases compatible with dominant inheritance and 
1–2% of sporadic PD cases. LRRK2 linked PD patients show clinical and neurochemical 
indistinguishable phenotype from sporadic affected ones. Up to date, LRRK2 protein is the 
most significant identified player in PD pathogenesis. Despite its predominance in PD, the 
physiological function of LRRK2 is not known, and therefore its precise role in the etiology 
of PD is far from being understood. Recent studies suggest a potential role of LRRK2 in 
vesicle trafficking. Subcellular fractionation and confocal analysis demonstrate the 
presence of LRRK2 in microsomal, synaptic vesicle–enriched and synaptosomal cytosolic 
fractions from animal brain, as well as the mitochondrial outer membrane. Moreover 
perturbations of LRRK2 expression have been shown to influence neurite extension and 
vesicle endocytosis. Finally, LRRK1 (Leucine Rich Repeat Kinase 1), the LRRK2 closest 
homologue, affects the EGF receptor (EGFR) endosmal trafficking. LRRK1 and 2 share 
protein domain organization and enzymatic activity typology although LRRK1 is not 
reported to be involved in PD pathogenesis. The assessment of a contingent crosstalk 
between these two proteins is still a gap in the field. 
Objectives and models: My research focuses on studying LRRK2 role in the secretion 
process, neurotransmitter release and receptors trafficking. In order to study these aspects 
I used the following models: i) to study dopamine (DA) release, PC12 cells expressing LRRK2 
WT or bearing pathological mutations under inducible promoter control. These cells are a 
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good model to investigate  neurotransmitter release mechanisms since they share the 
same secretion system with dopaminergic neurons; ii) SH-SY5Y or HEK-293 cells transiently 
co-transfected with murine growth hormone (mGH) expressing construct as a secretion 
reporter and LRRK2 WT or mutant; iii) HEK-293 or SH-SY5Y, transiently co-transfected with 
construct coding for Dopamine Receptor D1 (DRD1) and LRRK2 WT or mutant; iv) Striatum 
and hippocampus from WT or transgenic G2019S LRRK2 mice. Finally, I conducted a 
functional redundancy study between LRRK2 and its closest homologue LRRK1, in respect 
to EGFR trafficking. EGFR and dopamine receptors (DAR) are members respectively of 
tyrosine kinase receptors family and G protein coupled receptors family. For this study I 
developed a confocal microscopy assay making use of different SH-SY5Y cell lines: LRRK2 
Knock-Down (KD)  stably expressing GFP-LRRK1, LRRK1 KD SH-SY5Y stably expressing GFP-
LRRK2, or stable SH-SY5Y co-expressing a KD control construct and GFP-LRRK1 or 2  . 
Experimental approach and results: LRRK2 is reported to interact with a broad range of 
proteins involved in synaptic functions, cytoskeleton dynamics, and vesicular trafficking, 
moreover previous work done in the laboratories have provided different hints of a 
potential role of LRRK2 in vesiscle trafficking . However, up to date, the physiological 
function of LRRK2 is elusive. The main topic of my PhD thesis was to figure out which role 
has LRRK2 in the vesicle trafficking using the following secretion reporter assays: SH-SY5Y 
were transiently co-transfected with mGH and WT or mutant LRRK2 both pathological and 
kinase dead. After 24 hours of protein expression, growth medium and cell lysates were 
collected and the mGH secretion level was measured in presence of WT or mutant LRRK2. 
The results demonstrate that expression of WT or pathological mutant LRRK2 determines 
an increase in basal GH extracellular level, moreover this increase is greater in presence of 
the pathological G2019S mutation. Furthermore the LRRK2 effect on mGH secretion is 
absent when a LRRK2 kinase dead mutant is co-transfected. To further elucidate LRRK2 
kinase activity contribution in the observed mGH reporter secretion changes, the same 
assay was performed treating SH-SY5Y cells co-transfected with mGH and G2019S with the 
LRRK2 kinase inhibitor GSK2578215A. The presence of LRRK2 inhibitor significantly reduces 
the increase in GH extracellular level due to LRRK2 G2019S expression.  
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Neurotransmitter release has been studied in collaboration with a pharmacology research 
group of Department of Clinical and Experimental Medicine - University of Sassari - that has 
performed all the microdialysis experiments. To control LRRK2 expression in PC12, the Tet-
ON system was used. Upon induction with doxycycline to obtain LRRK2 expression, cells 
were treated with nicotine to induce dopamine release. Direct measuring of dopamine 
released was performed by microdialysis. Main result of this set of experiments is that the 
pathological mutant G2019S determines a significant DA extracellular level increase 
compared to WT in both basal and nicotine induced condition. The same PC12 model was 
utilized to study vesicle distribution by Electron Microscopy (EM). Resultant images play up 
a significant increase of the electron-dense vesicles in the proximity of the plasma 
membrane in presence of G2019S mutant. These vesicles are probably recruited for 
docking phase of exocytosis process. 
Vesicle trafficking regulates different cellular functions, including neurotransmitter or 
protein release and localization of membrane receptors. The previous results prompted me 
to analyze the possible effect of LRRK2 on membrane receptor localization using the 
membrane levels of DRD1 as a read-out. SH-SY5Y cells were transfected with plasmid 
coding for DRD1 in absence or in presence of LRKK2 G2019S, LRKK2 D1994A (kinase dead 
mutant), LRRK2 R1441G, or LRRK2 completely lacking the kinase domain (ΔKIN LRRK2). 48 
hours after transfection, the sub-cellular distribution of D1DR receptors from cell lysates 
was analyzed by purification of different cell components. The presence of LRRK2 G2019S 
or R1441G and, to a lesser extent, LRRK2 D1994A or WT determines a significant increase 
in the level of membrane-associated DRD1 compared to DRD1 alone, while the effect is 
completely abolished in presence of the ΔKIN mutant. Interestingly all these results seem 
to be evident only in neuronal cells since they are not displayed in non-neuronal cell lines 
such as HEK-293. 
To extend the analysis to a more physiological system I analyzed the distribution of two 
neurotransmitter receptors in the striatum of transgenic LRRK2 G2019S mice compared to 
non-transgenic ones. In particular, I analyzed the NMDA-NR1 receptor (NR1) and DRD1 
distribution in total, membrane or vesicle fractions obtained from the striatum of 5 
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different animals of the two genotypes. LRRK2 G2019S expression leads to a significant 
increase of DRD1 in membrane fraction paralleling a significant decrease in vesicle fraction, 
with no significant differences in total protein extracts between the two genotypes. No 
significant differences among the different fractions were observed for NR1, clathrin or 
sec8, a member of the exocyst complex.  
In line with these results on vesicle trafficking, I developed a confocal microscopy assay to 
assess functional redundancy between LRRK2 and LRRK1 in respect to EGFR trafficking. 
SHSY5Y KD for one of the two proteins but expressing a GFP fusion of the homologue one 
are treated with EGF-Rhodamine conjugate to track the receptor internalization. GFP-
LRRK1 is co-localizing with EGFR in both LRRK2 KD or control conditions. On the opposite, 
LRRK2 does not co-localize with EGFR in control condition as well as in LRRK1 KD 
background. Thus LRRK2 seems not able to compensate for LRRK1 function in EGFR 
internalization process. This result has been validated by two-way ANOVA analysis. At the 
moment I am developing a similar assay to investigate the role of LRRK1 or 2 on dopamine 
receptor trafficking. 
 
LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
5 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 










LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
6 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 
Studi di Sassari 
 
1.1 PARKINSON DISEASE 
 
Parkinson Disease (PD) is a chronic, neurodegenerative, progressive disease. The main 
neuropathological features are the extensive and selective loss of neurons in the 
Substantia Nigra pars compacta (SNpc) and the presence of intraneuronal proteinacious 
cytoplasmic inclusions, termed “Lewy Bodies” (LBs). The cell bodies of nigrostriatal neurons 
are in the SNpc, and they project primarily to the putamen (in the striatum). The loss of 
these neurons, which normally contain conspicuous amounts of neuromelanin, produces 
the classic gross neuropathological finding of SNpc depigmentation (Figure 1B)(2). 
Dopamine (DA) depletion in the striatum and neuron loss in SNpc are also responsible of 
the characteristic motor symptoms of PD: tremor at rest, rigidity, postural instability and 
bradykinesia. At the onset of symptoms, striatal DA is depleted of ≈80%, and ≈60% of SNpc 
dopaminergic neurons have already been lost. Nevertheless, the neurodegeneration is not 
limited to the SNpc but extends to other encephalic sub regions including noradrenergic 
neurons in the locus coeruleus and serotoninergic neurons in the nucleus basalis (2).  
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Incidence of PD is estimated in about 20/100000 cases per year in the population over 50 
years, up to 120/100000 new cases per year among the over 70 years old (2). Sometimes, 
differences in incidence are observed between different ethnic groups probably due to 
disease etiology namely linked to environmental risk factors exposure or genetic 
susceptibility. The average age onset is about 60 years, even if 4% of patients display an 
early disease development (before 50 years). Furthermore, since the clinical features of PD 
emerge only when a high percentage of SNpc neurons is compromised and the striatal DA 
levels are strongly reduced, it is plausible that epidemiology studies underestimate the 
disease incidence. 
Parkinson Disease has an heterogeneous nature, there are slow and fast progression forms; 
relatively simple symptomatology beside clinically complex forms. 
Indeed Parkinson forms are classified into: Primary Parkinson, Parkinson Plus and 
secondary parkinsonism (see table 1) (3) 
Idiopathic PD, also known as Primary Parkinson, is characterized by rigidity, resting tremor, 
slowness of movement, rigidity and balance loss. This form of pathology has slow progress 
rate and at present there are no external causes ascribable to the symptomatology.  
In life, the diagnosis of PD is made on clinical features, but definite diagnosis requires the 
identification of both LB and SNpc dopaminergic neuron loss. LBs are not specific for PD, 
however, and are also found in AD, in a condition called “dementia with LB disease” and as 
an incidental pathologic finding in people of advanced age at a greater frequency than the 
prevalence of PD (3). LBs are spherical eosinophilic cytoplasmic protein aggregates 
composed of numerous proteins, including α-synuclein, parkin, ubiquitin, and 
neurofilaments, and they are found in dopaminergic neurons in all affected brain regions (4, 
5). LBs are more than 15 µm in diameter and have an organized structure containing a 
dense hyaline core surrounded by a clear halo. Electron microscopy reveals a dense 
granulovesicular core surrounded by a ring of radiating 8–10 nm fibrils (6). 
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Vascular: multi-infarct state 
Trauma 
Infectious: post encephalitic 
Toxin: Mn, CO, MPTP, Cyanide 
Drug induced: dopamine antagonist and depletors 
Parkinson 
Plus 
Progressive sopranuclear palsy 
Multiple System Atrophy Syndromes 
Diffuse Lewy Bodies Disease 
Table 1. Parkinson forms. 
 
Another parkinsonism form is “Parkinson Plus”. In this category are grouped some 
neurodegenerative disorders showing a strict clinical similarity with PD, but characterized 
by concurrent presence of other neurological aspects (cerebellar, pyramidal, vegetative, 
cognitive). The most important among the Parkinson Plus manifestations are: Progressive 
sopranuclear palsy, Multiple System Atrophy Syndrome and the corticobasal degeneration 
(7). 
The last parkinsonism category is Secondary Parkinsonism. These forms display similar 
characteristics to PD, have known etiology, variable progress and a very low prevalence. 
Secondary Parkinsonisms can be induced by toxins (Manganese, carbon monoxide, 
cyanide), drugs (neuroleptics, antiemetics, calcium blockers), or traumatic brain damages 
(i.e. Pugilistic Parkinson). Drug-induced parkinsonism are marked out by the lack of 
neuronal loss and are subject to remission after drug assumption interruption. On the 
contrary, neurotoxins damage to the SNpc is irreversible (8). All Secondary Parkinsonisms 
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are characterized of a very fast clinical development, lacking or reduced drug response and 
no Lewy Bodies presence in respect to the Primary  Parkinson forms. 
For years, diagnostic criteria for idiopathic Parkinson Disease have been developed. 
Recently Gelb and colleagues have reviewed them highlighting how clinical diagnosis of PD 
is established on the presence of cardinal motor symptoms in combination with the 
exclusion of specific uncharacteristic symptoms. Among motor cardinal signs:  
- Resting tremor 
- Rigidity 
- Bradykinesia 
- Asymmetric onset 
- Postural instability. 
Lastly, also the responsiveness to levodopa (L-Dopa) is considered. This is, with sporadic 
exceptions, a necessary but not exclusive requisite for PD diagnosis, inasmuch is observed 
also in atypical forms of the disease (9, 10).    
 
1.2  DOPAMINE AND DOPAMINE RECEPTORS 
As mentioned before, a progressive demise of the dopaminergic cells in the SNpc is 
observed in post-mortem brains of PD patients. From SNpc the dopaminergic neurons form 
synapses mainly with neurons of the striatum (another nucleus of the basal ganglia). This 
system constitutes the nigrostriatal pathway, which regulates the extrapyramidal system 
designated to the movement, posture and balance minding control (11). 
Dopamine is synthetized by dopaminergic cells in SNpc (pre-synaptic level) (12, 13), thus, in 
the parkinsonian patient, SNpc cells degeneration dramatically drops dopamine production 
and dopamine levels in the striatum producing all the motor symptoms which characterize 
the pathology.  
.  
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1.2.1 Dopamine synthesis and metabolism 
Dopamine, together with adrenaline and noradrenaline, constitutes the catecholamine 
neurotransmitter class. They are all synthetized starting from tyrosine through a shared 
pathway including five enzymes: the tyrosine-hydroxylase, an aromatic amino acid 
decarboxylase; the dopamine β-hydroxylase; the pteridine-reductase and the 
feniletanolamina-N-methyltransferase. The first enzyme in the pathway, the tyrosine-
hydroxylase, converts the amino acid tyrosine to L- dihydroxiphenilalanine (L-DOPA). At the 
next step of the pathway, the L-DOPA is decarboxylated by the DOPA-decaroxylase 
obtaining dopamine and CO2.  The dopamine β-hydroxylase converts dopamine in 
norepinephrine. 
 
Once synthesized in the SNpc neurons, dopamine is stored in vesicles and released in the 
inter-synaptic space, where is free to interact with DA receptors (both at pre and 
postsynaptic level) and exert its action. Dopamine activity is terminated with a process 
called “re-uptake” at the presynaptic terminal. In this process dopamine is transported in 
the presynaptic neuron by the dopamine transporter (DAT), and, is degradated by two 
enzymes: the monoamine-oxidase (MAO) and the catechyl-O-metyl-transferase (COMT). 
The MAOs are localized in the external mitochondrial membrane, albeit other MAOs are 
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also present outside the dopaminergic neuron, respectively MAO A and MAO B; whereas 
the COMT are extraneuronal enzymes that inactivate catecholamines by methylation of the 
hydroxyls on the catechol ring (Figure 2). 
 
1.2.2  Dopamine receptors trafficking 
Dopamine receptors belong to the large family of heptahelical transmembrane spanning G 
protein-coupled receptors (GPCRs). Five mammalian dopamine receptor subtypes have 
been identified and are classified into two major groups, the D1- (D1 and D5) and D2- (D2, 
D3, D4) like receptors (14, 15).  
Although dopamine receptors are 
similar in structure, receptor 
subtypes differ by their affinity for 
dopamine and coupling to 
downstream effectors, including 
heterotrimeric guanine nucleotide-
binding proteins (G proteins) (14, 
16). Dopamine receptor subtypes 
are expressed differentially 
throughout the brain. Among the 
D1-like receptors, D1 receptors are 
the most abundant, with mRNA 
transcripts found in the neostriatum, nucleus accumbens, and olfactory tubercle. Lower 
levels of D1 receptor mRNA are found in the cerebral cortex, hypothalamus, and thalamus 
(14). Among the D2-like receptors, D2 receptors are the most abundant, with mRNA 
transcripts found in the neostriatum, nucleus accumbens, and olfactory tubercle, as well as 
the midbrain, including the substantia nigra and ventral tegmental area (14). 
The canonical mechanisms for GPCRs signaling, reviewed in (17) can be extended to 
dopamine receptors D1 and D2. 
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Binding of ligands (such as hormones, neurotransmitters or sensory stimuli) induces 
conformational changes in the transmembrane and intracellular domains of the receptor 
thereby allowing interactions with heterotrimeric G proteins. Activated GPCRs act a 
guanine nucleotide exchange factors (GEFs) for the α subunits of heterotrimeric G proteins, 
catalyzing the release of GDP and the binding of GTP for G protein activation. The activated 
G protein subunits (α•GTP and βγ) can then associate with downstream effectors (17) 
including second messengers like adnylate cyclase and ion channels, to modulate various 
aspects of cellular physiology. A distinguishing feature of D1- and D2-like receptors is their 
differential coupling to heterotrimeric G proteins. In many cell types D1-like receptors 
couple to Gαs, which activates adenylate cyclase (52, 53) while D2-like receptors couple to 
the pertussis toxin-sensitive Gαi or Gαo, which inhibit adenylate cyclase (48, 54) 
G protein-mediated signaling by agonist-activated GPCRs can be terminated through GPCR 
phosphorylation by GPCR kinases (GRKs) and concomitant GPCR association with arrestins, 
which interact with clathrin and the clathrin adaptor AP2 to drive GPCR internalization into 
endosomes (see figure 4 from (17)) Finally, G protein activity is terminated by GTP 
hydrolysis and the re-formation of the G protein heterotrimer. GPCR internalization 
regulates the functional process of receptor desensitization (17), a process that determines 
the end of the GPCR signaling. 
Following internalization after association with arrestins, GPCRs can be trafficked to 
lysosomes, where they are ultimately degraded, or to recycling endosomes for recycling 
back to the cell surface in the functional process of re-sensitization — whereby the cell is 
re-sensitized for another round of signaling.  
GPCR internalization is heavily influenced by two of the canonical families of GPCR-
interacting proteins, the GRKs and the arrestins. However, certain other GPCR-interacting 
proteins can also regulate the endocytic trafficking of GPCRs in a more receptor selective 
manner. For example, the GPCR-associated sorting proteins (GASPs) promotes D2R 
trafficking to lysosomes following agonist stimulated endocytosis (17).  
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Dopamine receptor-mediated signaling is a tightly regulated process that is highly 
dependent on the accessibility of receptors to agonist binding at the cell surface. This 
availability of functional surface receptors is governed by a strict balance of the various 
intracellular receptor trafficking pathways that, in association with receptor sensitivity, 
work in concert to regulate the amplitude of agonist-mediated cellular responsiveness (14). 
It has been demonstrated that GPCRs are not static within the plasma membrane but can 
move in the plane of the membrane by the passive process of lateral diffusion (18-20). One 
of the key factors that govern the dynamics of lateral diffusion of GPCRs is their association 
with other cellular proteins. The formation of these protein complexes can serve to restrict 
the movements of the GPCRs, effectively stabilizing the receptors in specific microdomains 
within the membrane, such as the synapses for example. Movement by lateral diffusion 
has been reported for several GPCRs including dopamine D1 receptors. In cultured 
neurons, approximately 65% of D1 receptors are mobile with the remaining receptor 
anchored within the membrane. This ratio of mobile vs anchored receptors is not fixed, but 
fluctuating. Scaffolding proteins have a role in this process, either stabilizing DA receptors 
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1.3 TREATMENT 
Current PD medication treat symptoms none halt or retard dopaminergic neuron 
degeneration. The main obstacle to developing neuroprotective therapies is a limited 
understanding of the key molecular events that provoke neurodegeneration (2).  
 
1.3.1 Drug Therapy 
As mentioned above, to date, no defined neuroprotective treatment for PD influencing the 
natural progressive course of the disease has been established. Therefore current 
treatments aim at correcting the dopaminergic deficit in the Substantia Nigra either 
through (i) the substitution of dopamine via its precursor levodopa, or (ii) the prolongation 
of the synaptic availability of dopamine via inhibitors of enzymes of the dopamine 
metabolism: COMT (catechyl-O-metyl-transferase) and MAO B (monoamine-oxidase B), or 
(iii) the activation of functional relevant receptors via dopamine-agonists (21). 
 
Levodopa 
Levodopa (L-dopa) is the most effective drug in the treatment of PD and virtually all 
patients benefit from this treatment (21). L-dopa is the natural parent for dopamine, it 
enters in the dopaminergic neurons that convert it into dopamine. Direct administration of 
dopamine as a drug is not possible as it is not able to pass the hematoencephalic barrier 
and thus reach the dopaminergic neurons. The L-dopa is orally administered and absorbed 
in the bowel, and finally enters the systemic circulation. The L-dopa decarboxylase, outside 
of CNS, catalyzes the transformation of L-dopa into dopamine by removing its carboxylic 
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group. Since dopamine has no therapeutic effect at peripheral level rather unpleasant side 
effects, L-dopa is routinely administered in combination with a decarboxylase inhibitor to 
avoid peripheral L-dopa decarboxylase activity.  Once in the brain, L-dopa is converted in 
dopamine by neuronal L-dopa decarboxylase in the cytoplasm, here is actively transported 
in the synaptic vesicles. Dopamine storing in vesicles avoids its enzymatic degradation by 
MAO and it is essential for the following release of the neurotransmitter in the inter-
synaptic space upon neuronal stimulation. When the impulse reach the dopaminergic 
neurons, the vesicles fuse their membrane 
with the neuronal plasma membrane  
releasing dopamine in the synaptic space, 
where it can reach the receptors on the post-
synaptic neurons and complete its therapeutic 
activity. 
Although levodopa represents the gold 
standard in PD therapy, chronic levodopa 
treatment is known to result in motor 
complications (dyskinesia, dystonia) or neuropsychiatric problems in later stage of disease 
(21). 
Dopamine agonists 
Dopamine agonists are a class of drugs that share the capacity to directly stimulate 
dopamine receptors. This class of therapeutics compounds offers some advantages over 
levodopa therapy as the reduced incidence of levodopa-related adverse effects, no 
requirement of metabolic conversion and potential neuro-protective benefits. However, the 
anti-Parkinson efficacy is limited and motor complications are not completely prevented. 
COMT inhibitors 
To date, the entacapone is the only substance available in this therapeutic class and it is 
administered in association with levodopa as previously described. COMT inhibitors exert 
their therapeutic effects via inhibition of peripheral levodopa catabolism and therefore 
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increasing levodopa bioavailability. Thus, COMT inhibition is associated with an increased 
stability of levodopa plasma levels, suppressing peaks of levodopa concentrations, which 
are thought to be associated with motor complications (21).  
MAO B inhibitors 
The most diffused MAO B inhibitor in PD therapy is selegiline; it is a selective inhibitor of 
the oxidative catabolism of dopamine via irreversible inhibition of the monoamine-oxidase 
B. Therefore selegiline amplifies the effect of levodopa. In experimental studies selegiline 
was not only able to improve parkinsonian symptoms but also to exert some 
neuroprotective effects on dopaminergic neurons. However, clinical studies on the efficacy 
of this therapeutics have produced controversial results (21).  
 
1.3.2  Surgical therapy 
Recent advances in neurosurgery and imaging techniques have allowed the development of 
novel therapeutic approaches for PD. In general there is a main recently developed 
approach to the surgical therapy of PD: the deep brain stimulation (21) is a surgical 
treatment involving the implantation of a medical device called a brain pacemaker, which 
sends electrical impulses to specific parts of the brain. 
 
1.4 ETIOLOGY 
Parkinson Disease has a complex and multifactorial etiology, involving genetic and 
environmental factors. However the molecular details of the degenerative process are still 
barely known even though the discovery of PD related genes has shed new light on the 
cellular mechanisms that might be affected in the PD neurodegeneration. 
 
 
LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
17 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 
Studi di Sassari 
 
1.4.1 Environmental Factors 
The environmental etiology hypothesis posits that PD-related neurodegeneration results 
from exposure to some dopaminergic neurotoxins. Theoretically, the progressive 
neurodegeneration in PD could be produced by chronic neurotoxin exposure or by limited 
exposure initiating a self-perpetuating cascade of deleterious events (2). An example of 
how an exogenous toxin can mimic the clinical and pathological features of PD is the MPTP 
(1-methyl-4-phenyl-1, 2, 3, 6,-tetrahydropyridine or meperidine) intoxication (22). The 
discovery of MPTP as dopaminergic neurotoxin date in 1982 when young drug users 




(MPPP), an analog of 
the narcotic Demerol 
(22) in which MPTP 
was present as 
contaminant. In 
humans and monkeys, 
MPTP produces an 
irreversible and severe 
parkinsonian syndrome characterized by all the PD features, including tremor, rigidity, 
slowness of movement, postural instability and freezing. In MPTP-intoxicated individuals 
the beneficial response to levodopa and development of long-term motor complications to 
medical therapy are virtually identical to those seen in PD patients.  Similar to PD, MPTP 
susceptibility increases with age and is observed the same topologic pattern in the damages 
to the dopaminergic system (2) (23, 24) In PD, dopaminergic neurons seem to be more 
sensible to degeneration in respect to other neuronal populations in the brain, these 
neurons are also more susceptible to MPTP induced degeneration (2). All these clinical 
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manifestations on MPTP intoxication corroborates the environmental hypothesis of PD 
etiology and the MPTP-treated monkeys became a good model for PD studies. Some of 
these studies unraveled the MPTP mechanism of toxicity. After systemic administration, 
MPTP, which is highly lipophilic, cross the blood-brain barrier. Once in the brain the pro-
toxin MPTP is oxidized to 1-methyl-4-phenyl-2, 3, -dihydropyridinium (MPDP+) by MAO-B in 
the glia, and probably by spontaneous oxidation it becomes MPP+, the active toxic 
molecule. Thereafter it is released in the extracellular space by an unknown mechanism. 
Finally is concentrated into dopaminergic neurons through its high affinity for the 
dopamine transporter (DAT). Inside neurons MPP+ can follow at least three routes: (i) it can 
bind to the vesicular monoamine transporter-2 (VMAT2 ) (25), which translocate MPP+ into 
synaptosomal vesicles; (ii) it can be concentrated within the mitochondria (26) and (iii) it 
can remain in the cytosol to interact with the cytosolic enzymes (27). The toxic mechanism 
of MPP+ is carried out in the mitochondria where damages electron transport chain (see 
figure 7). Here MPP+ blocks complex I, which interrupts the transfer of electrons to 
ubiquinone. This perturbation enhances the production of ROS species and decreases the 
synthesis of ATP with the final result of apoptosis in the neurons (2, 22).  The MPTP toxicity 
mechanism supports the idea of an involvement of the mitochondria and oxidative stress in 
PD pathogenesis. 
Many epidemiologic studies have been done to clarify if toxin exposure can cause PD. 
Subject of these studies have been pesticides and insecticides with structure similar to 
MPP+ as paraquat and rotenone but none of these studies reported unmistakable results. 
So far, there is no clear evidence that exposure to herbicides or insecticides can cause PD. 
Other epidemiological studies reported that cigarette smoking and coffee drinking are 
inversely associated with the risk of PD development.  Based on the apparent protective 
effect of smoking, the therapeutic effect of nicotine has been tested in a few clinical trials, 
but no improvement of motor symptoms with transdermal nicotine treatment has been 
documented (28).  
Another possibility, which does not fit into a genetic or environmental category, is that an 
endogenous toxin may be responsible for PD neurodegeneration. Distortions of normal 
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metabolism might create toxic substances due to environmental exposures or inherited 
differences in metabolic pathways. One source of endogenous toxins may be the normal 
metabolism of DA, which generates harmful reactive oxygen species (ROS)(29). Consistent 
with this hypothesis is the report that patients harboring specific polymorphisms in the 
gene encoding xenobiotic detoxifying enzyme cytochrome P450 may be at higher risk of 
developing young onset PD (30). Further, toxic derivatives of isoquinoline have been 
recovered from PD brains (2, 31).  
In addition to toxins, other environmental factors, which can be considered as risk factors 
rather than causative elements, are lifestyle and habits. For instance, repetitive or simply 
violent traumas can provoke a parkinson-like progressive syndrome as the one frequently 
observed among boxers from which the name “Pugilistic Parkinson Syndrome”.  Another 
two risk influencing factors are age and sex, males are indeed more affected in respect to 
women (in a 1,5:1 ratio). In humans, neuronal and SNpc neuromelanin loss increases 
around 60 years, coinciding with the average age of PD onset. Since neuromelanin has a 
protective effect in neurons against free radicals and toxins, the decrease in this pigment 
may predispose the brain of aged people to Parkinson (32).    
Finally, it has been hypothesized an infective etiology: clinical manifestations similar to PD 
have been observed in patients affected, in the past, by a viral encephalitis propagated in 
pandemic in 1920 (33, 34). 
 
1.4.2 Genetic Factors 
For a long time Parkinson Disease has been considered a sporadic disease, until Leroux in 
1880 tracked recurring PD cases in the same family. This observation led to the hypothesis 
that hereditary factors could increase susceptibility to the pathology.(28). In the last decade 
several genome wide association studies allowed the identification of numerous mutations 
in different genes in families with mendelian inheritance parkinsonisms. These findings 
have been made possible through the analysis of rare familial PD forms characterized by 
clinical and neuropathological features sometimes different from idiopathic forms. More 
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recently some susceptibility loci for PD have been identified, but further analysis are 
required to confirm their association with Parkinson Disease (35, 36). 
Up to date, 16 mendelian transmission forms of Parkinson Disease are known.  Some of 
them have an autosomal dominant (AD) inheritance pattern while others have an 
autosomal recessive (AR) one. Gene products have been associated to 10 out of these 16 
forms whereas other causative (PARK 3) or predisponent (PARK 10, PARK 12, PARK 16) 
chromosomal loci are still waiting to be linked to a precise gene product (37) (See table 2).   
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Mendelian inheritance Parkinson forms and associated genes 
Although genetic PD forms represent only a little percentage of the total cases, studies on 
cellular or animal models based on the expression familial Parkinson gene have importantly 
contributed to elucidate disease etiopathology. In this session, the main characteristics of 
PD associated genes are described, giving particular relevance to those ones that are widely 
accepted to be conclusively associated with mendelian forms of the disease (35) and have 
been more extensively studied (PARK1/4, PARK2, PARK5, PARK6, PARK7). For a more detailed 
presentation of PARK8 locus see paragraph 1.5. 
 
- Alpha-synuclein (SNCA or α-Syn) - PARK1/PARK4 
Although Lewy bodies (LB) represent one of the principal landmarks of PD, and their first 
observation date to 1912, only in 1997 Alpha Synuclein has been identified as the most 
important component of these protein inclusions (5). In the same year, 1997, the 
identification of SNCA as the first gene implicated in PD resulted from linkage analysis in the 
‘‘Contursi’’ kindred, with the point mutation A53T being associated with the disease in this 
family. Since then, two other point mutations, A30P and E46K, as well as duplications and 
triplications of the SNCA gene, have been identified among PD patients. The point 
mutations and gene rearrangements result in rare autosomal dominant, middle to late 
onset PD. The loss of dopaminergic neurons and the presence of Lewy bodies, not only in 
the Substantia Nigra, but also in the Locus Coeruleus, have been observed in the SNCA 
linked PD (35).  
The SNCA gene has six exons, encoding an abundant 140 amino acid cytosolic protein, 
which is found at presynaptic terminals and thought to be involved in synaptic function 
(35). Despite intensive studies, the exact role of α-SYN at the synapse remains elusive. 
There is evidence that the protein plays a role in maintenance of synaptic vesicle pools and 
activity-dependent dopamine release (1), Larsen et al.(38) have provided evidence that α-
SYN might modulate synaptic vesicle priming. Nevertheless α-SYN knockout mice have little 
or no obvious phenotype. 
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The α-synuclein protein is organized in three distinct domains: an N-terminal amphipathic 
region with conserved repeats (KTKEGV), a central hydrophobic NAC domain (non-amyloid 
component), and an acidic C-terminal region. All the three point mutations are located in 
the amphipathic region and are believed to exacerbate the toxic protofibril and fibril 
formation. Indeed, monomeric mutant a-synuclein has the propensity to form stable β-
pleated sheets; the ensuing fibrillogenesis (formation of oligomers, protofibrils, and finally 
fibrils), results in the generation of pathological inclusions, known as Lewy bodies. 
Moreover, dopamine has been shown to modulate -synuclein aggregation, perhaps 
explaining the selective vulnerability of the Substantia Nigra in PD.  
Studies in drosophila indicate that Lewy bodies may be a way of detoxifying the cell of 
damaged -synuclein. The enhanced toxicity of mutant -synuclein may also be explained 
by the assembly of oligomeric -synuclein into annular structures (39), that integrate into 
cellular membranes to form pores, thereby affecting membrane permeability. Of note, the 
overexpression of the wild-type protein is sufficient to cause PD, as duplications or 
triplications of the wild-type SNCA produce the disease in patients (35) although the 
precise relationship between aggregation, cellular dysfunction and cell death underlying PD 
is unknown (1). 
 
- Parkin - PARK2 
A year after the discovery of the SNCA gene, Parkin has been associated with PD (35). It is 
one of the largest genes in the human genome, mapping 1.38 Mb and comprising 12 exons 
(18). The Parkin gene encodes an ubiquitous 465 amino acid protein (35) organized in 
domains: an N-terminal ubiquitin like domain, a central linker region and C-terminal RING 
domain consisting of two RING finger motifs separated by an in between RING domain (19).  
Parkin functions as an E3 ubiquitin protein ligase similar to other RING finger containing 
proteins by targeting misfolded proteins to the ubiquitin proteasome pathway for 
degradation, and the loss of its E3 ligase activity due to mutations lead to autosomal 
recessive early-onset PD. Parkin functions as a neuroprotective protein in a variety of toxic 
LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
23 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 
Studi di Sassari 
insults crucial for dopamine neuron survival (19); it is therefore conceivable that the loss of 
parkin function may lead to the accumulation of a nonubiquitinated substrate, which is 
deleterious to the dopaminergic cell, but, due to its nonubiquitinated nature, does not form 
typical Lewy bodies (20). 
Parkin interact with several  presynaptic proteins (summarized by Moore (40). α-SYN and 
the α-SYN-binding synaptic protein (SNCAP) synphilin are two prominent examples. In 
addition parkin has been shown to modulate the function of a G-protein coupled receptor 
(GPR37) that interacts with the dopamine transporter DAT (1). The molecular events 
generated by mutated Parkin that lead to neuronal degeneration seem to be in this order: 
accumulation of substrates and other proteins, proteasome inhibition and cellular death. 
Actually, animal models allowed disclosing a possible additional role of Parkin in 
mitochondrial maintenance and oxidative stress prevention in cooperation with another 
PD-associated protein, PINK1 (see hereinafter). In particular, PINK1 would be involved in 
mitochondrial membrane integrity maintenance and could assist Parkin in the removal of 
damaged proteins. 
Finally, oxidant molecules, among which dopamine itself, are able to alter Parkin solubility 
leading to its aggregation (41).  
 
- Ubiquitin carboxyl-terminal esterase L1, UCHL-1 - PARK5 
A mutation in Ubiquitin carboxyl-terminal esterase L1 gene was identified in affected 
members of one single family of German ancestry. To date, no other bona fide pathogenic 
mutations of this gene have been found. Whether UCHL1 really is a PD-responsible gene is 
not yet clear. Interestingly loss of UCHL1 function leads to neurodegeneration in mice (1). 
UCHL-1 is an abundant brain enzyme; its function might correlate with polymeric ubiquitin 
recycling and its conversion into monomeric units. Mutations in PARK 5 gene cause 
enzymatic activity reduction of UCHL-1 with consequent proteasome activity alteration 
(42). 
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- PTEN-induced kinase 1, PINK-1 - PARK6 
This gene is particularly interesting within the context of the findings linking PD to 
mitochondrial dysfunction and oxidative stress, as PINK1 is a mitochondrial protein kinase.  
The PINK1 gene encodes a 581 amino acid ubiquitous protein, consisting of an N-terminal 
34 amino acid mitochondrial targeting motif, a conserved serine–threonine kinase domain 
and a C-terminal auto regulatory domain. The majority of the identified mutations are in 
the kinase domain, indicating the importance of PINK1 enzymatic activity in PD 
pathogenesis (35). 
 A substrate of PINK1 has been recently identified as TNF receptor-associated protein 1 
(TRAP1). TRAP1 is a mitochondrial molecular chaperone, also known as heat shock protein 
75. Wild-type PINK1 has been shown to phosphorylate TRAP1, moreover this 
phosphorylation is significantly increased in response to oxidative stress induced by H2O2. 
Interestingly, the PD-linked PINK1 mutants, G309D or L347P, abolish this kinase activity, 
although not affecting either the PINK1-TRAP1 interaction or their mitochondrial co-
localization. Overexpression of wild-type PINK1 further revealed that cytochrome c release 
from mitochondria was reduced under oxidative stress conditions. TRAP1 is therefore 
proposed as being a downstream effector of PINK1: when phosphorylated by PINK1, TRAP1 
may indirectly suppress cytochrome c release from mitochondria, protecting against 
oxidative stress-induced cell death (43). It is therefore plausible to assume that Parkin, 
PINK1, and TRAP1 are interacting in the same signaling pathway, the defects of which may 
lead to PD. 
PINK1 seems to be involved in another important protection mechanism against oxidative 
stress, once again acting in concert with another protein, htrA2, which is a serine protease 
located in the mitochondria. PINK1 phosphorylates htrA2 thus tuning its proteolytic activity 
which in turn contributes to increased cell resistance to oxidative stress (44).  More 
recently, Wang et al. described a new mechanism trough which PINK1, immobilizing 
damaged mitochondria, confines cellular damages produced by ROS species to a little 
region in the cell, putting damaged organelles to quarantine prior to their definitive 
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removal by autophagosome. Cells are able to maintain their energy balance preventing 
oxidative stress injuries by fine tuning of trafficking, distribution and clearance of 
mitochondria. PINK1 acts in the control of this balance intervening on mitochondrial 
motility.  Specifically, it has been demonstrated that PINK1 phosphorylates the protein 
Miro, which is  part of a complex anchoring the kinesin to the mitochondrial surface, thus 
controlling mitochondria transport alongside the axon (45). In fact phosphorylated Miro is 
targeted for degradation in a Parkin-dependent pathway.  Removal of Miro from the 
mitochondrion also detaches kinesin from its surface arresting the damaged mitochondria 
until their complete degradation occurs, likely by autophagosome engulfment.  This PINK1-
Parkin activity is fundamental for ensuring the removal of damaged organelle preventing 
the injury  diffusion in a larger area in the cell (46, 47). As a consequence, neurons defective 
for PINK1 and/or Parkin show an impairment in mitochondrial clearance which makes them 
susceptible to degeneration (42, 48).   
 
- DJ-1 - PARK7 
Parkinson Disease form 7 is one of the rare AR parkinsonisms with juvenile onset. Clinical 
features associated to PARK7 gene are very similar to those linked to PARK2 except for the 
presence of psychiatric symptoms. This gene, located in chromosome 1 encodes a 189 
amino acids protein identified as DJ-1 by Bonifati et al. in 2003. It has ubiquitous expression 
in a variety of mammalian tissues including brain and it localized into mitochondria (49). 
The wild type form is present as homodimer located in the cytosol, nucleus and 
mitochondria, but upon oxidative stress conditions it is relocated in the matrix and in the 
intermembrane space of the mitochondrion where it exerts a protective activity against 
ROS. Many lines of evidences suggest that DJ-1 functions as an antioxidant protein. 
Oxidative stress leads to an acidic shift in the DJ-1 isoelectric point by oxidation of Cys106 
which can be converted to cysteine sulfinic acid (Cys-SO2H). Because of its inherent ability 
to undergo self-oxidation to eliminate H2O2 it may function as a scavenger of reactive 
oxygen species (ROS). In fact overexpression of wild-type DJ-1 both in cell culture and 
dopaminergic neurons in vivo protects against wide variety of toxic injury due to oxidative 
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stress. DJ-1 also functions like a redox-dependent chaperone to inhibit -synuclein 
aggregation and subsequent cell death. Some familial DJ-1 mutants may have altered 
abilities to undergo key oxidative modifications, namely, a decreased propensity to undergo 
oxidation at position 106, and/or an increased susceptibility to undergo oxidative 
modifications with potentially deleterious effects on DJ-1(49) protective function. 
 
1.5 LEUCINE RICH REPEAT KINASE 2 – (LRRK2) 
 
1.5.1 Physio-pathological Role of LRRK2 (PARK8) 
PARK8 locus have been associated for the first time to PD in 2002, by Funayama’s group 
(50), in a Japanese family presenting a autosomal dominant form of parkinsonism without 
Lewy Bodies presence. Two years later two other groups independently have identified the 
gene LRRK2 in the PARK8 locus (51, 52); subsequently many pathological mutations have 
been identified.  
LRRK2 mutations are usually associated to clinical parkinsonism – with typical movement 
problems of tremor, rigidity, bradykinesia and postural instability. Where autopsies have 
been performed, prominent loss of melanised dopaminergic neurons in the Substantia 
Nigra pars compacta has been noted. As might be expected, movement problems in these 
patients respond to L-DOPA treatment. PD cases due to LRRK2 mutation are therefore 
similar to sporadic PD and distinct from some other types of inherited parkinsonisms. 
Most, but not all, cases appear to have Lewy bodies, the characteristic pathology of α-
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LRRK2 : general features and domains 
The LRRK2 coding gene is located in chromosome 12 (12.q12), is composed of 51 exons 
giving rise to a 2527 amino acid protein consisting of 7 functional conserved domains 
(figure 10)(54, 55) : 
 An “Armadillo Repeats” domain; 
 An “Ankirin Repeats” domain; 
 A “Leucine Rich Repeats” (LRR) domain, composed of a 22-28 amino acids motif 
repeated 13 times; 
 A Roc domain with GTPase activity; 
 A Carboxy Terminal of Roc (COR) domain   
 A kinase domain, with homology with MAP-Kinase-Kinase-Kinase (MAPKKK) 
 A C-terminal WD40 domain.  
 
The ”Armadillo Repeats” domain is composed by a repeated 42 amino acids motif 
organized in 3 α-helixes and was firstly identified in the “Armadillo” protein of Drosophila, 
which human homologous is β-catenin. The Armadillo domain forms a versatile molecular 
interaction platform available for different protein interactors (56). 
The “Ankirin Domain” consists of seven ankyrin repeats, each forms two antiparallel helices 
followed by a β-hairpin or loop (Figure 8 - a from Mata et al 2006). The repeats stack 
together to form a gently curved structure in the ankyrin repeat domain. Ankyrin repeats 
are found in diverse bacterial and eukaryotic proteins, including cytoskeletal proteins, 
transcription factors, signaling proteins and cell cycle regulators (57).  
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Each of the 13 identified LRRs in the leucine rich repeat domain is predicted to form a β-
strand followed by an α-helix that line up side-by side to form an arch-like structure (Figure 
8 - b from Mata et al. 2006). LRR domains participate in the interactions with different 
proteins through binding to their extended solvent-accessible surface (58). 
The WD40 domain is composed by repeated motifs of 40 amino acids, mainly tryptophan-
aspartate. Each repeat contains a four-stranded, antiparallel β-pleated sheet and together 
these repeats form a circular bladed propeller-like structure. The predicted WD40 domain 
of LRRK2 comprises seven WD40 repeats (Figure 9 - a modified from Mata et al. 2006). This 
seven-bladed propeller is thought to form a rigid platform for reversibly interacting with 
proteins, possibly including those that contain other WD40 domains. The WD40 domains 
are the most common repeats found in human proteins and normally they coordinate the 
assembling of multi proteic complexes. They have been identified in functionally diverse 
proteins including the Gβ subunit of heterotrimeric G proteins, transcriptional regulators, 
protein phosphatase subunits, RNA processing complexes, cytoskeletal assembly proteins, 
and proteins involved in vesicle formation and trafficking (58) 
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Catalytic domains of protein kinases are long 250-300 amino acid residues, containing a 
small N-terminal lobe and a larger C-terminal lobe connected by a hinge-like region to form 
a cleft in which Mg2+ -ATP and the protein substrate binds (Figure 9 - b - modified from 
Mata et al. 2006). The activation segment is composed of 20–35-residues within the large 
C-terminal lobe. The majority of protein kinases require phosphorylation of the activation 
segment for full activity. Upon phosphorylation, the activation segment is believed to 
adopt an active conformation, enabling substrate access and catalysis to take place (58). 
The putative GTPase domain of LRRK2 belongs to the ROCO family, in which the predicted 
GTPase (Roc) is always found in tandem with the COR domain, the function of which is still 
unknown. This Roc–COR module is conserved throughout evolution, suggesting the 
functional interdependence of the two domains. The Roc-GTPase domain of the LRRK2 
resembles most closely the GTPases of Rab family, which have been implicated in vesicular 
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trafficking and transport (58) processes by acting as molecular/regulatory switches that 
cycle between GTP and GDP-bound conformations (59). A functional link is postulated to 
exist between the intrinsic GTPase activity and downstream kinase activity. Different 
studies have suggested that LRRK2 kinase activity is dependent on the existence of a 
functional GTPase domain, whereas GTPase activity can function independently of the 
kinase domain (59). An additional hypothesis proposes that GTPase activity would be able 
to regulate the kinase activity and/or the kinase activity would have the ability to regulate 
the GTPase activity by an auto-phosphorylation mechanism. In support of this latter 
hypothesis are the various studies that assess auto phosphorylation ability of LRRK2. The 
kinase domain is indeed not only able to phosphorylate some potential substrates but also, 
with highest efficacy, the protein itself in correspondence to the ROC domain (see figure 10 
from Rideout et al. (55)).  
Dimerization of the ROC or ROC-COR domains results in an intermolecular interaction 
between the kinase domains subsequently allowing an increased kinase activity, thereby 
structurally explaining the interplay between these enzymatic domains. Dimerization of 
LRRK2 has been demonstrated by yeast two-hybrid analysis, native gels, size exclusion 
chromatography and co-immunoprecipitation from mammalian cells (59, 60) 
The presence of multiple protein interaction domains (armadillo, ankyrin, LRR and WD40) 
suggests that LRRK2, in addition to its predicted protein kinase and GTPase activities, might 
serve as a scaffold for assembly of a multiprotein signaling complex. However, because 
these domains bind diverse proteins ranging from transcription factors to signaling 
proteins (58), the physiological LRRK2 interactors and substrates and its function remain 
unknown.   
Recent mRNA expression analysis studies demonstrate the LRRK2 transcript presence in 
the brain and in various peripheral districts. In rodents, high levels of LRRK2 mRNA have 
been detected in brain and lymph nodes. LRRK2 is particularly abundant in the dopamine-
innervated areas as (53) cortex, striatum, cerebellum, hippocampus and olfactory tubercle; 
while lower levels are observed in the substantia nigra (55). The subcellular localization of 
LRRK2 is mainly cytosolic with an important component associated with the membranes, 
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vesicles and cellular organelles as Golgi, mitochondria, lysosomes and RE, as well as 
microtubules and cytoskeleton structures (61) 
 LRRK2 pathological mutations do not alter protein stability and/or localization but some of 
them increase the kinase activity; they are, in particular, clustered in the central part of the 
gene in the ROC GTPase domain and the kinase domain (36). An increase in the LRRK2 
kinase activity appears to be sufficient to generate neuronal toxicity implicated in PD (54, 
59, 62). Studies performed on cell lines demonstrate that LRRK2 has long half-life, and, 
especially if co-expressed with Parkin, tends to form aggregates which are prone to 
ubiquitination through a process involving Parkin (63) 
More the 75 variants of LRRK2 are described, but not all of them are PD-causative 
mutations. On the other hand some mutations are associated to PD and they are localized 
in the enzymatic region of the protein (figure 10 from Rideout et al): The ROC domain is 
affected by multiple mutations: R1441G, R1441C, R1441H) (52). The effects of these 
mutations result in an alteration of GTPase activity, but the final effect of these alterations 
on the kinase activity are quite contrasting. In the ROC domain only a pathological 
mutation has been described (Y1699C) while in the kinase domain there are two adjacent 
mutations, G2019S and I2020T. G2019S is the most common pathogenic substitution in the 
familial forms of PD but is also associated to sporadic forms (36, 64, 65). Various studies 
performed on cellular models have consistently showed that this substitution leads to an 
increase in kinase activity up to threefold.  The 2019 residue is indeed located in a loop 
which is closing like a string the catalytic site, the substitution of glycine with serine forces 
the catalytic site in a constitutively active state leading probably to the increased kinase 
activity (59, 66).  
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From the first association between LRRK2 and PD in 2004, many epidemiologic studies 
have assessed that LRRK2 is responsible of roughly 10% of PD familial forms and 
importantly also the 4% of the sporadic ones. The glycine to serine substitution in 2019 
position of LRRK2 represents the most frequent substitution in the Caucasian population; it 
is indeed responsible for 1-2% of idiopathic PD and 6% of familial PD; moreover, G2019S 
mutation is higher in some population of North Africa and in Ashkenazi Jews (13-41% 
sporadic cases and up to 40% of familial ones)(67).  
Concerning Sardinia, a study published in 2006 by Cossu et al. shows that G2019S 
substitution is present in the highland with a lower frequency in respect to other 
mediterranean population, while R1441C is very uncommon in Sardinian population (68).  
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LRRK2 physiologic function and involvement in Parkinson Disease 
Despite the extensive studies performed, up to date, the physiological role of LRRK2 
remains elusive. Among these studies, very indicative of the possible function of LRRK2 are 
the identifications of potential protein interactors. Through different methodological 
approaches and various models, a plethora of interactors has been suggested; a summary 
of those is given in table 3, which link LRRK2 to a broad range of cellular functions.  Inter 
alia, more than one group found that LRRK2 phosphorylates moesin, suggesting that LRRK2 
can take part in neurite length maintenance (69, 70). Moesin is a member of ERM 
(Ezrin/Radixin/Moesin) protein family which main function is to anchor the actin 
cytoskeleton to the plasma membrane; moesin and radixin are indeed implicated in neurite 
elongation. In fact, LRRK2 pathological mutant expression causes neurite shortening and 
neurite branching inhibition (69, 71). In C. elegans, LRK-1, the worm homologue of LRRK2, 
plays a role in vesicle trafficking between axons and dendrites (72). 
Other data support the hypothesis that LRRK2 is involved in cytoskeleton dynamics. Hyper-
expressed LRRK2 co-immunoprecipitates with endogenous tubulin in HEK-293 cells.  
Furthermore, G2019S mutant is able to phosphorylate tubulin more than the WT protein 
leading to microtubules anomalies that interfere with the normal neuronal functionality 
(73). Studies using LRRK2 transgenic mice models describe an abnormal Golgi apparatus 
fragmentation, which integrity is maintained with the help of microtubules, with 
consequences on Golgi and endoplasmic reticulum balancing in vesicular trafficking control 
(70). Microtubule stability and integrity are fundamental both for cellular morphology 
maintenance and for molecules and organelles transport that in neurons must cover longer 
distances in respect to other cellular types.  
Moreover Leucine Rich Repeat Kinase 2 might be involved in translation control, since it 
has been shown to interact with the 4E-BP1 translation initiation factor. 
Furthermore LRRK2 seem to be implicated in apoptosis activation by interaction with FADD 
proteins and caspase (74, 75). Iaccarino et al. demonstrated that G2019S expression in SH-
SY5Y cells causes neuronal death by mitochondrial dependent apoptosis mechanism. This 
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is carried out by caspase 3 activation depending on Apaf1 which together with pro-caspase 
9 and cytochrome c participate in the apoptosome formation (75). In this study ETNA-/- 
cells had been used as control. These cells are deficient for Apaf1 and are a common 
cellular model for apoptosis studies in neurodegenerative diseases. When ETNA -/- are 
transfected with LRRK2G2019S   the lacking of Apaf1 prevents caspase 3 activation and the 
nucleus condensation while cytochrome C is as usual released from the mitochondria. 
These results point at a pivotal role of the mitochondria in LRRK2 mutant induced cell 
death and indicate Apaf1 as a fundamental mediator in this pathway. In the same study 
Iaccarino et al. have analyzed the differential role of LRR and WD40 LRRK2 domains in 
LRRK2 mutants toxicity showing that the presence of these two domains (LRRKΔLRR or 
LRRK2ΔWD40 ) are essential for caspase 3 activation and cellular apoptosis.  
An interesting study of Greggio et al. demonstrates that PD causing mutants of LRRK2 
increase LRRK2 tendency to form cytoplasmic inclusions in cellular models (76) and this 
property seems to be linked with the kinase activity of the protein (64). Cellular proteic 
inclusions in neurons of PD patients bearing LRRK2 mutations suggest that one effect of 
PARK8 locus alterations can be the protein aggregation.  
According to different studies there might be a common pathologic mechanism involving 
LRRK2 and α-Synuclein. The α-Synuclein deposited in Lewy bodies is indeed abundantly 
phosphorylated on Serine 129. Up to date, LRRK2 is not able to directly phosphorylate α-
synuclein although Qing at al. were able to co-immuniprecipitate LRRK2 and α-synuclein 
from Lewy bodies positive tissues and oxidative stressed HEK-293 cells (77). Furthermore 
recombinant α-synuclein is phosphorylated by some kinases present in the protein lysates 
from HEK-293 expressing LRRK2 (77, 78). Finally, SH-SY5Y co-transfected with LRRK2 (WT or 
G2019S) and α-Synuclein show an increase in aggregation level, phosphorylation and 
release of α-synuclein (79). Taken together these data corroborate a current hypothesis of 
an important functional connection between LRRK2 and α-Synuclein in triggering 
neurodegeneration causing PD (80). 
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Very useful tools to gather clues on the physiopathology of LRRK2 are animal models.  In D. 
melanogaster, overexpression of mutant LRRK2 causes loss of dopaminergic neurons, 
retinal degeneration, motor impairment and shorter life, whereas wild-type protein 
produces less severe phenotypes (53). In C. elegans models, overexpression of LRRK2 also 
causes phenotypic changes, including axonal damages in neurons, which seem to involve 
altered mitochondrial functions (53). Knockout of the nearest homologous gene in 
Drosophila produces variable effects, with loss of dopamine cells reported in one study, 
but this was not replicated in an independent laboratory. Knockout of the C. elegans 
homologue causes changes in axonal polarity and in neurite outgrowth in response to 
stress (53). Three independent mouse knockouts have been reported (80-82). In all three 
published studies, the brains of the animals were reported to be grossly normal and there 
was no loss of dopaminergic neurons in the substantia nigra. Therefore, LRRK2 appears to 
be dispensable for the survival of neurons under both basal and stressed conditions. 
Different LRRK2 transgenic rodents have been generated by independent groups. In a few 
cases the authors describe dopaminergic degeneration in animals expressing pathological 
mutants (83, 84) while sometimes a reduction in dopamine extracellular content was 
observed (83, 85, 86). More recently, two groups have reported that transient 
overexpression of mutant LRRK2 using viral vectors will result in loss of dopaminergic 
neurons in the substantia nigra of mice (87) or rats (88). Importantly, wild-type protein or 
kinase-dead versions of LRRK2 had no effect, suggesting that simple overexpression of any 
similar large protein would not be sufficient to cause neurodegeneration (53). Therefore, 
this approach has the potential to provide a model that more fully replicates the 
phenotypes seen in human LRRK2 patients than are not seen in conventional transgenic 
models. A feature shared by various murine models of PD is an abnormal level of 
phosphorylated protein Tau induced by G2019S and R1441G LRRK2 mutants. The Tau 
protein binds tubulin and promotes its assembly in microtubules; when phosphorylated, 
Tau induces on the contrary, microtubule fragmentation that damages the entire 
cytoskeleton network (85) (89). Finally, the blockage of Zebrafish LRRK2 protein by 
morpholinos caused embryonic lethality and severe development defects such as growth 
retardation and loss of neurons. In addition, the deletion of WD40 domain of zebrafish 
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LRRK2 revealed Parkinsonism-like phenotypes, including loss of dopaminergic neurons in 
the diencephalon and locomotion defects. Remarkably, another group failed to reproduce 
the phenotypic loss of dopaminergic neurons in zebrafish (90) 
 
LRRK2 and vesicle trafficking 
Different experimental approaches have demonstrated that LRRK2 is localized throughout 
the cytoplasm of neuronal perikarya and dendritic processes, where it is associated with 
vesicular and membranous structures, the microtubule network, mitochondria and other 
membrane-bound organelles (61, 91). Moreover it has been demonstrated its association 
with lipid rafts. Although the pathological mutations do not affect the LRRK2 membrane 
association, this localization is of particular interest since the lipid rafts play important roles 
in cellular functions such as signal transduction, membrane trafficking and cytoskeletal 
organization (92). Furthermore, lipid rafts associate with SNARE (soluble N-ethylmaleimide-
sensitive fusion protein-attachment protein receptor) proteins and regulate endocytosis 
and exocytosis (93, 94). Lastly, an extensive analysis of LRRK2 subcellular localization 
performed by Biskup et al in 2006 either in primary cortical neurons or rodent brains 
showed that LRRK2 co-localizes consistently to Golgi apparatus and Golgi-associated 
vesicles, endoplasmic reticulum (ER), lysosomes and mitochondria, and, to a significantly 
lesser degree, to vesicle markers such as synaptotagmin. 
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Table 3: Molecular interactors of LRRK2 and co-localizing organelle markers. Abbreviations: MS: 
Mass Spectrometry; Y2H: Yeast Two Hybrid; SV: Synaptic Vesicle; OE: Over Expression; KD: Knock 
Down; RP recycling Pool; GNEF: Guanine Nucleotide Exchange Factor; P: 
Phosphorylation/Phosphate; WB: Western Blot; Co-IP: CoImmunoPrecipitation; ICC: 
ImmunoCitoChemistry; Mut: mutant/mutation. 
Protein Potential role Technique Analysis/Expression 
System 
REF. Notes 
Tubulin-β §  
(Tubβ)  
Kinase Substrate In vitro assay  (hLRRK2 from insect cells + 
βTubuline from Bovine Brain) 
(73) 
- G2019S 3xP Tubβ. 
- In vitro co incubation bovine 
brain tubulins + LRRK2 ↑stability 
microtubules. 
- LRRK1 does not P βTub. 
Tubulin-β § Interactor 
CoIP+MS 
Mouse brain WT and LRRK2 









screen) (an in vitro 
assay)  
P assay and MS 
 Rat brain extracts (95) - LRRK2 WT does not P Moesin. 
- The minimum catalytically active 
fragment ofLRRK2 requires an 
intact GTPase, COR and kinase 
domain,  WD40 motif and a C-
terminal tail. 


















Rat brain extracts (95) LRRK2 WT does not P Radixin 
Rab5b  
(but not with 
Rab4a) 
Interactor Y2H 




and HEK cells 
(96) - a fraction of both proteins co-
localize in SV 
- Interaction increased by GTPgS 
- Alteration of LRRK2 expression 
impairs SV endocytosis  
NSF Interactor Co-IP With endogenous LRRK2 in 
Mouse Brain 
(97) -All these interact with WD-40 
Domain; 
 
-LRRK2 silencing alters storage 
and mobilization SV in the RP 
 
-LRRK2 KD increase recycling Syn 
number (Electrophysiology SiRNA 
cortical neurons) 
 
NSF Interactor GST pull-down + LC 
MS/MS 
 
GST-LRRK2 Domains on mouse 
brain 
(97) 
Sub cell fractionation Cortical neurons lysates 





Interactor GST pull down GST-LRRK2 Domains on mouse 
brain 
(97)  
Synapsin 1 Interactor 
GST pull down 
GST-LRRK2 Domains on mouse 
brain 
(103) 
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Interactor GST pull down 
 





Actin  Interactor GST pull-down GST-LRRK2 Domains on mouse 
brain 
(103) 
F-Actin and actin 
regulatory 
proteins  







All proteins Endogenous in 
NIH3T3 (fibroblast) cells. 
(98) 







Validated: WB IP 
All proteins Endogenous in 
NIH3T3 cells. 
(98) LRRK2 binds F-Actin and effect its 
polymerization in vitro 
KD LRRK2 determines neurite 
shortening. 




Validated: WB IP 
Endogenous LRRK2 in NIH3T3 
cells. 
(98)  




Validated: WB IP 
All proteins Endogenous in 
NIH3T3 cells. 
 (98)  
EndoA  Kinase substrate 
 
purified human 
LRRK2 in a 33P-ATP 
in vitro assay 
Drosophila (99)  
EndoA  
 







Lrrk2 negatively controls EndoA 
membrane association 









In vitro: LRRK2 transfected 
HEK-293; in vivo: brain lysates 
wt and LRRK2 KO mice 
 and in Drosophila 
(106)  
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ArfGAP1 
 





for Pi release in vitro 
 
In vitro (100) WD-40 + KIN. 
- ArfGAP1 binds LRRK2 and ↑ 




ArfGAP ↑GTP Hydrolysis. 
 
In vivo Mouse brain WT and lrrk2 KO 
  
  
Co-IP Mouse Brain endogenous 
LRRK2 














HEK293 (101)  
In vitro -ARHGEF7 enhances R1441C’s 
GTP affinity 
 ARHGEF7 enhances WT’s GTP 
hydrolysis  
FADD Interactor Co-IP 293T cells 
 
(74) -Interaction enhanced by LRRK2 
pathological mutations 
WT mice brain  




Co-localization ICC COSI cells (91)  
Ὺ adaptin (TGN) Co-localization ICC COSI cells (91) No mutant effect on 
EAA1 (Early 
Endosomes) 
Co-locazation ICC COSI cells (91) No mutant effect on 
Lysotracker 
(Lisosomes) 
Co-localization ICC COSI cells (91) No mutant effect on 
MytoTracker 
(Mitochondria) 




Co-localization ICC -mouse primary 
cultured neurons 
-COSI cells 
(91) No mutant effect on 
Nr1a Interactor WB Mouse Brain (91) No mutant effect on 
Synaptophysin Interctor WB Mouse Brain (91) No mutant effect on 
Thy-1.2,GM1, 
phosphatidylino
sitol (Lipid Rafts) 
Co-localization ICC Mouse cortical Neurons (91) No mutant effect on 
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Rab5b  Subcell 
fractionation+WB 
ICC -  
Rat cortex Lysates  
293T cells,  
Rat hippocampal Neurons 
(96) -No mutant effect on 
-Rab5 rescues LRRK2 OE/KD 
endocytosis defect 
SNCA Co-localization Immunostraining Human post mortem brain (77)  
SNCA Interactor Co-IP Co-transfected HEK-293 under 
oxidative stress conditions  
(77) - Co-IP is not validated in brain 
extracts 
SNCA Kinase Substrate WB with anti 
phospho antibodies 
In vitro (78) -LRRK2 P SNCA at Ser-129 
-G2019S LRRK2 has grater P 
capacity on SNCA  




LRRK2 from Swiss 
3T3 
cells 
Hek-293 (102) - 14-3-3 binds P-Ser 910 and P-Ser 
935  
- Mut abolish binding but not  
G2019S 
- Binding disruption cause 
cytoplasmic aggregation. 
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To elucidate the 
physiological role of 
LRRK2, Piccoli et al. 
(97) analyzed the 
presynaptic and 
postsynaptic 
properties of cortical 
neurons in which 
LRRK2 had been 




analysis of these 
neurons revealed that 
LRRK2 silencing alters 
synaptic transmission. 
In the same study, a 
structural analysis of this system revealed LRRK2 silencing perturbs vesicle dynamics and 
distribution within the recycling pool, determining a significant decrease in docked vesicles, 
but an increase in the amount of vesicle recycling, (an overview of vesicle dynamics at the 
nerve terminal is represented in figure 11 from (103)). At the molecular level, LRRK2 
interacts, mainly through the WD40 domain, with a number of proteins involved both in 
endo- and exo-cytosis of synaptic vesicles (see table X). Unfortunately, under the same 
experimental conditions, the overexpression of LRRK2 is toxic, therefore not allowing a 
comparative analysis between protein absence and overexpression. Besides many of those 
proteins are presynaptic proteins: NSF that catalyzes the release of the SNARE complex and 
allows the first step of the endocytic cycle; the AP-2 subunit of the clathrin complex which 
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is one of the major pathways for synaptic vesicles (SV) recycling from the membrane to the 
resting pool; the glycoprotein SV2A, that together with SV2B, controls the storage and 
mobilization of SV in the readily releasable pool; and the synapsin that are thought to 
immobilize SV in the reserve pool by crosslinking vesicles to the actin cytoskeleton (97). 
Among LRRK2 identified interactors, Rab5 is interesting because involved in SV endocytosis 
regulation. In general Rab proteins are GTPases localized in vesicular cellular 
compartments with regulatory role in the membrane trafficking. Rab5 has a key role in 
carrying endocytic vesicles from plasma membrane to early endosomes (104). Shin et al. 
have characterized in depth the Rab5-LRRK2 interaction (96) measuring endocytosis and 
exocytosis speed in hippocampal neuronal cells transfected with LRRK2 WT or mutants 
revealing a decrease in endocytosis but no effect on exocytosis of synaptic vesicles. This 
effect on endocytosis is recovered co-transfecting Rab5, but it is not if co-transfected the 
Q79L mutant form of Rab5, which is not able to hydrolyze GTP (96).  
            Two independent groups have recently identified ArfGAP1 (ADP-ribosylation factor GTPase-
activating protein 1) as a specific LRRK2 interactor both in vivo and in vitro (100, 105). 
Interestingly, ArfGAP1 promotes the GTP hydrolysis of Arf1 (ADP-ribosylation factor 1), a 
small GTPase that is critical for maintaining normal Golgi morphology, and Arf1 GTP 
hydrolysis is also required for the dissociation of coat proteins from Golgi-derived 
membranes and vesicles (106). 
An alternative explanation for the dysregulation of vesicle trafficking could arise from the 
described role of LRRK2 in the modulation of cytoskeleton dynamics. Both the microtubule 
and actin cytoskeletons make essential contributions to intracellular vesicle and organelle 
motility (107). There are two mechanisms for actin-based motility (92). First, actin 
polymerization itself can propel vesicles, and, secondly, actin serves as a track for the 
motor protein myosin belonging to ERM (ezrin/radixin/moesin) family. In fact, LRRK2 
modulates both ERM protein phosphorylation and actin polymerization mainly in filopodia 
structures (108). 
Cytoskeletal dynamics, motor protein function and vesicle trafficking are all regulated 
through the Rab, Arf and Rho families of GTP-binding proteins. Notably, LRRK2 contains a 
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GTP-binding domain and interacts with ArfGAP1, a protein regulating the GTP hydrolysis of 
Arf1 (106), leading to the interesting possibility that LRRK2 may affect, directly or 
indirectly, the secretory and endocytic pathways modulating cytoskeleton dynamics and 
vesicle motility. 
Moreover LRRK2 appears to be localized in different intracellular districts that play a critical 
role in the control of vesicular trafficking: ER, Golgi apparatus and associated vesicles, 
cytoskeleton, lipid raft and finally lysosomes (Figure 12 from (109)). 
 
Although some results are somewhat contradictory or difficult to interpret, it is evident 
that LRRK2 participates in a protein network regulating synaptic vesicle trafficking. Vesicle 
trafficking is a complex process regulating multiple different cellular functions, in addition 
to neurotransmitter release, such as neurotrophic factor release, localization of membrane 
receptors, changes in plasma membrane composition at the cell surface and, not least, 
organelle biogenesis. The molecular mechanisms regulating the exo/endo-cytosis for 
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proteins or membranes are different from those regulating neurotransmitter release. The 
LRRK2 cellular localization mainly with the ER and the Golgi apparatus and Golgi-associated 
vesicles, but to a significantly lesser degree with vesicle markers (61), could suggest an 
involvement of LRRK2 in anterograde or retrograde vesicle trafficking between the ER and 
Golgi apparatus or Golgi and cell membrane or Golgi and lysosomes, rather than a simple 
control of neurotransmitter release at synapse. 
 
1.6 LEUCINE RICH REPEAT KINASE 2 AND LEUCINE RICH REPEAT KINASE 1   
In vertebrates, the LRRK2 gene has one paralogue: LRRK1 (leucine-rich repeat kinase 1). 
The two proteins display a conserved domain architecture and are both members of the 
ROCO family. ROCO proteins were formally described and named by Bosgraaf and Van 
Haastert in 2003 (110). Both proteins are expressed in the brain and are highly 
phosphorylated. However, despite their close homology and their similar expression 
profile, no mutations in LRRK1 have been genetically associated with PD. This group of 
proteins contains two conserved domains named ROC (Ras of complex proteins), a GTPase 
domain with high sequence similarity to Ras and other related small GTPases, and COR (C-
terminal of ROC), a domain of unknown function, that represents a fingerprint of all ROCO 
proteins (111).  
LRRK1 and LRRK2 share a similar domain organization, which includes a serine-threonine 
kinase domain, C-terminal of ROC (COR) domain together with a ROC domain, and leucine-
rich and ankyrin-like repeats at the N-terminus. The major differences between LRRK1 and 
LRRK2 are at the N-terminal region, where LRRK2 has a large number of unique repeats 
and unique phosphorylated consensus binding sites for 14-3-3. There are important 
differences also in the C-terminal regions that show the lowest degree of homology 
compared to other domains (Fig. 13 from (112)). This divergence may be relevant with 
respect to a recently proposed pre-synaptic function of LRRK2, which was shown to 
interact with a number of presynaptic proteins via its C-terminal WD40 domain (112). 
Previous studies have shown that both LRRK1 and LRRK2 bind GTP, are basally p  
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hosphorylated in cells and share a similar cytoplasmic distribution. Overall, the absence of 
a complex and extended N-terminal region from LRRK1, the minimal similarity of the C-
terminal tail and the lack of homologous residues for 14-3-3 binding may represent 
important differences that affect protein function (111). On the other hand, the ROC–COR–
kinase domain architecture is clearly preserved in both proteins, thus biochemical data 
obtained for LRRK1 may help to elucidate the molecular mechanism leading to LRRK2-
dependent PD (111). In a recent study, Civiero et al. suggest that the sequence similarity 
between LRRK1 and LRRK2 is reflected in functional similarity for some domains. From 
their biochemical characterization study emerged that GTP binding affinities of LRRK1 and 
LRRK2 were comparable using an isotopic displacement assay. While both LRRK proteins 
can bind to ATP as predicted for kinases, their kinase activity revealed striking differences. 
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In particular they could not observe LRRK1 kinase activity toward itself or against generic or 
LRRK2 specific substrate; concluding that LRRK1 phosphorylation properties are 
fundamentally different from those of LRRK2, substrate specificity differs and while 
autophosphorylation is robust in LRRK2, it is not likely to play a significant role for LRRK1. 
Therefore, although the kinase domains are similar for LRRK1 and LRRK2, at the functional 
level the two proteins are likely to be very different (112). More than this, Civiero et al. 
show that highly purified LRRK1 and LRRK2 can associate in dimeric structures in absence 
of their molecular partners confirming other similar previous results, inter alia those of 
Dachsel et al. (113) which also suggested that the LRRK2 dimer is the functional unit. 
However, results on LRRK1 and LRRK2 localization in tissues are slightly discordant. Until 
the last months the results of several studies analyzing LRRK mRNA and protein levels in 
different tissues and organs indicate that the expression of the two proteins generally 
overlaps and, in some tissues, levels are comparable (113, 114). However, in organs such as 
the brain and the kidneys, LRRK2 mRNA expression is higher than that of LRRK1 (115). If 
LRRK1 and LRRK2 possess partially overlapping functions, then LRRK1 may compensate for 
the effects of LRRK2 deficiency only in those tissues where their expression is similar, but 
not in the brain or kidneys where LRRK1 expression is low. Giesert et al. examined the 
distribution of Lrrk2 and Lrrk1 mRNA the adult brain of Mus musculus, and also compared 
Lrrk1 and Lrrk2 expression in the same tissues drawing the anatomical localization of both 
proteins (116). The mesencephalic region of the substantia nigra, which contains the most 
vulnerable neuronal populations affected in PD, exhibited only moderate Lrrk2 expression 
in the adult brain while the target area of these dopaminergic neurons (i.e. caudate 
putamen in the striatum) shows the highest level of Lrrk2 mRNA. In contrast to Lrrk2, Lrrk1 
was barely detectable in the adult mouse brain. From these and other observations it is 
well established now that, despite their high degree of homology and their comparable 
expression patterns during development, the adult brain almost exclusively expresses 
Lrrk2. Nevertheless, this finding suggests that LRRK1 does not compensate for LRRK2 
function in the adult. Furthermore it may also explain why, up to now, no PD-associated 
mutation has been identified in LRRK1 (116). 
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At present, little is known about LRRK1 biochemical properties. The cellular function of 
LRRK1 has been much less investigated because LRRK1 is not clearly linked to a human 
disease. In 2011, Hanafusa et al. (117) published an elegant paper demonstrating that 
LRRK1 plays a role in endocytosis of epidermal growth factor receptor (EGFR). In this study, 
it was shown that LRRK1 forms a complex with activated EGFR through an interaction with 
Grb2 (growth-factor-receptor-bound protein 2). In addition, LRRK1 regulates EGFR 
transport from early to late endosomes. Of note, LRRK1 was found to interact with proteins 
involved in the dynein-mediated endocytosis process.  
Taken together, these observations imply that LRRK1 and LRRK2 may share convergent 
functions, possibly acting as scaffolds but in different steps of the vesicle trafficking 
(111)(120) or in different tissues.  
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2.1 Materials 
Antibodies: anti-TH (1:4000 Sigma), anti-Myc (1:5000 Sigma), anti-DRD1 (1:2000 Sigma), 
anti-NR1 (1:2000 Sigma), anti-Sec8 (1:4000 BD-Biosciences), anti-clathrin (1:5000 BD-
Biosciences). 
Sheep anti-LRRK1 was obtained from Prof. Dario Alessi (University of Dundee, Dundee, UK) 
and used at 1:200. Anti-LRRK2 antibodies used were the rabbit monoclonal antibodies C41-
2 and UDD3 (antibody produced by Epitomics with the support of the Michael J. Fox 
Foundation) and used 1:1000) (118) 
Reagents: Tween 20 (Polyethylene glycol sorbitan monolaurate), Phenylmethanesulfonyl fluoride 
(PMSF), protease inhibitor cocktail and (2)-Nicotine hydrogen tartrate salt were obtained from 
Sigma-Aldrich. LRRK2 inhibitor GSK2578215A was from Tocris. The phosphate-buffered saline (PBS) 
solution was made using NaCl (137 mM), KCl (2.7 mM), Na2HPO4 (8.1 mM), KH2PO4 (1.47 mM), 
CaCl2 (1.19 mM), MgCl2 (0.54 mM), and glucose (7.5 mM) from Sigma and then adjusted to pH 7.4. 
Dulbecco’s modified Eagle’s medium (DMEM)–F12, Streptomycin/ Penicillin, Hygromycine B, 
Geneticin-G418 were purchased from Invitrogen and doxycycline from BD Biosciences. The 
tetracycline-free Fetal Bovine Serum (FBS) was from Lonza Sales Ltd (Switzerland). The blasticidin 
10 µg/ml (Invivogen, San Diego, CA, USA), and Gentamicin from Sigma. 
 
Cell lines and stable clones 
HEK293 human embryonic kidney cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum at 37°C and 5% CO2 . 
Human neuroblastoma SH-SY5Y cells (ATCC number CRL- 2266) were grown in DMEM-F12 
(Invitrogen), 10% fetal calf serum (FCS, Invitrogen) at 37°C and 5% CO2.  
For the microdialysis experiments a PC12-TET-ON cell line (Clontech Laboratories Inc) or 
PC12-TET-ON cell lines expressing the plasmid pTRE2 containing cDNAs coding for LRRK2 
variants (WT or R1441C or G2019S) were used.  The plasmid pTRE2 vectors containing 
LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
50 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 
Studi di Sassari 
cDNAs coding for LRRK2 variants (WT or R1441C or G2019S) were cotransfected with p-TK-
Hyg in a 8:1 molar ratio into PC12- TET-ON cells, using Lipofectamine LTX Reagent (Life 
Technologies) according to the manufacturer’s protocol. The different PC12-TET-ON clones 
were maintained under selection by 400 g/mL of G418 and 200 g/mL of hygromicin-B. 
Individual clones expressing both antibiotic resistances were picked after 14 days of 
selection, moved in a 96 well plate, and maintained in selective medium till confluence 
growth. Different individual clones were analyzed for LRRK2 expression upon induction by 
doxycycline (0.2 μg/mL). All the PC12-TET-ON and PC12-TET-ON derived cell lines (Clontech 
Laboratories Inc) were cultivated in DMEM-F12 supplemented with 10% Tetracycline-free 
FCS (Lonza) and maintained under selection by 200 μg/mL of G418 and 100 μg/mL of 
hygromicin-B at 37°C and 5% CO2. 
For the LRRK1-LRRK2 functional redundancy study a combination of four different cell lines 
derived from SH-SY5Y cells was used. Namely stably SH-SY5Y cells previously generated in 
the lab by co-transduction of lentiviral (LV) knockdown (KD) constructs (blasticidin 
selected) and a lentiviral construct for eGFP-LRRK1 or eGFP-LRRK2 expression following the 
scheme below. 
-   
Further information on the LV construct used for KD are reported in table 4 (note that the 
number immediately following the gene name refers to the position on the cDNA sequence 
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Name of oligonucleotide Oligonucleotide sequence 
Start position of the short 
hairpin sequence in 
target’s reference 
sequence 
sh1 miR30 LRRK1 S  
GAGCG GCCCAGGTCTCAGATGGAATTA 
TAGTGAAGCCACAGATGTA 
TAATTCCATCTGAGACCTGGGG T 6734 
sh3 miR30 LRRK2 S 
GAGCG AGCCAGAGGAAATGTCATTTAT 
TAGTGAAGCCACAGATGTA 
ATAAATGACATTTCCTCTGGCA T 6251 
 
Table 4: List of primers used to generate lentiviral vectors expressing short hairpin RNA (microRNA 
based). Forward and reverse primers are given, sequences depicted in bold correspond to the 
hairpin stem sequence containing the LRRK1 or LRRK2 target sequence, sequences given in italics 
are the loop sequence. 
 
Stably transduced SH-SY5Y human neuroblastoma cells used in the functional redundancy 
study were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
15% fetal bovine serum and 1x non-essential amino acids (Life Technologies) at 37°C and 
5% CO2. These cell lines co-express a blasticidin selection marker, thus growth medium was 
supplemented by blasticidin 10 µg/ml (Invivogen, San Diego, CA, USA). 
 
Animals 
LRRK2 G2019S transgenic mice were provided by prof. Ted M. Dawson Department of 
Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 
Mice were housed and treated in strict accordance with the NIH Guide for the Care and 
Use of Laboratory Animals. All animal procedures were approved by the Institutional 
Animal Care and Use Committees of the Johns Hopkins Medical Institutions (Animal 
Welfare Assurance No. A3272-01). Mice were maintained in a pathogen-free facility and 
exposed to a 12 h light/dark cycle with food and water provided ad libitum  
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2.2 Methods 
Plasmid constructions 
The plasmids for inducible expression of LRRK2 were obtained by digestions of cDNAs 
corresponding to human LRRK2 (WT or R1441C or G2019S) in fusion with 5X myc repeats 
[26] with BamHI and XhoI and subcloned in BamHI/EcoRV cloning sites in pTRE2 vector 
(Clontech). 
cDNA coding for mouse growth hormone (GH, NM_008117.2) was RT–PCR amplified from 
mouse pituitary gland mRNA (oligo forward: ATCAGGATCCTTGGCAATGGCTACAGACTC, 
reverse: ATCAGGATCCGAAGGCACAGCTGCTTTCC), digested with BamHI restriction enzyme 
and cloned in BamHI cloning site of pCS2-5X-myc-tag containing the tag in C-terminal 
position. Plasmid pTL2-DRD1 (kindly provided by E. Borrelli, University of California, Irvine) 
was used as template for DRD1 cDNA, the PCR fragment oligo forward: 
ATCCTCGAGAAGATGGCTCCTAACACTTCTACCA, oligo reverse: 
CTCCTCGAGGGTTGAATGCTGTCCGCTGTG) was digested with XhoI and subcloned into 
pcDNA3.1-3X-flag-tag containing the tag in the C-terminal position. 
p-TK-Hyg (Clontech Laboratories Inc ) was used to provide hygromycin resistance to PC12 
ON cells. 
Use of restriction and modification enzymes 
The digestion reactions are usually assembled with 3 units enzyme/μg DNA and the specific 
reaction buffer. The incubation is performed for one hour at 37°C. After the digestion with 
appropriate enzymes, vectors are treated, at 37 °C for one hour, by CIP (Calf Intestinal 
Phosphatase, Promega), to remove phosphate groups at 5' ends of the linearized plasmid. 
Agarose gel electrophoresis 
The agarose is melted in 1X in TAE (40 mM Tris-HCl, pH [8.5], 1 mM EDTA, 20 mM acetic 
acid) and ethidium bromide (EtBr) is added at a final concentration of 0.04 μg/ml. DNA 
samples are loaded using loading buffer (0.04% bromophenol blue, 0.04% xylene cianol, 
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30% glycerol) and run at 120V. Nucleic acid bands are visualized under UV light. The size of 
the fragments is estimated in the presence of a ladder of known molecular weight. 
DNA purification from agarose gel  
Kit Wizard ® SV Gel and PCR Clean-Up System (Promega) are used to isolate a DNA 
fragment as folloes: excide the DNA bands from the agarose gel and place in a 1.5 ml 
microcentrifuge tube. Add Membrane Binding Solution (10μl/10mg of gel slice). Vortex and 
incubate at 50-65°C until gel slice is completely dissolved. Insert SV Minicolumn into 
Collection Tube. Transfer dissolved gel mixture to the Minicolumn assembly. Incubate at 
room temperature for 1�. Centrifuge at 16,000 ×g for 1’. Discard flow through and reinsert 
Minicolumn into Collection Tube. Add 700μl Membrane Wash Solution (ethanol added). 
Centrifuge at 16,000 ×g for 1’. Discard flow through and reinsert Minicolumn into 
Collection Tube. Repeat Step 4 with 500μl Membrane Wash Solution. Centrifuge at 16,000 
×g for 1’. Empty the Collection Tube and centrifuge again the column assembly for 1’ with 
the microcentrifuge lid open (or off) to allow evaporation of any residual ethanol. Carefully 
transfer Minicolumn to a clean 1.5 ml microcentrifuge tube. Add 50 μl of Nuclease-Free 
Water to the Minicolumn. Incubate at room temperature for 1’. Centrifuge at 16,000 ×g for 
1’. Discard Minicolumn and store DNA at 4°C or -20°C. 
Ligation reaction 
Ligase reaction is set up as follows: in a final volume of 15 μl, incubate 20-80 ng of 
linearized plasmid and a variable quantity of insert in the presence of 1 unit of T4 DNA 
ligase (Promega) in an appropriate buffer (Ligase buffer 10X, Promega). Evaluate, for each 
cloning, the optimal ratio vector/insert for the reaction. After an incubation O/N at 16°C, 
transform E. coli DH5 α cells with 5 μl of the reaction. 
Bacterial transformation 
The DH5apha strain cells were used. The reaction has been performed as follows: add 5 μl 
of a ligation reaction to 80 μl of competent cells. After incubation on ice for 30’, shock the 
cells at 37 °C for 3’, then incubate at room temperature for 10’. Add 500 μl of LB and 
LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
54 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 
Studi di Sassari 
incubate at 37 °C for 50’, centrifuge for few seconds to obtain a pellet and, eliminated 500 
ml of LB, dissolve the pellet. Plate cells on a selective solid medium (LB agar and 
appropriate antibiotic) and incubate O/N at 37 °C. 
Plasmid DNA purification (Miniprep) 
Wizard®Plus SV Minipreps DNA Purification System (Promega) is used to purify plasmidic 
DNA. Pellet 5 ml of overnight culture. Thoroughly resuspend pellet with 250 μl of Cell 
Resuspension Solution. Add 250 μl of Cell Lysis Solution to each sample; invert 4 times to 
mix. Add 10 μl of Alkaline Protease Solution; invert 4 times to mix. Incubate 5 minutes at 
room temperature. Add 350 μl of Neutralization Solution; invert 4 times to mix. Centrifuge 
at top speed for 10’ at room temperature. Insert Spin Column into Collection Tube. Decant 
cleared lysate into Spin Column. Centrifuge at top speed for 1’ at room temperature. 
Discard flowthrough, and reinsert Column into Collection Tube. Add 750 μl of Wash 
Solution (ethanol added). Centrifuge at top speed for 1’. Discard flowthrough and reinsert 
column into Collection Tube. Repeat washing step with 250 μl of Wash Solution. Centrifuge 
at top speed for 2’ at room temperature. Transfer Spin Column to a sterile 1.5 ml 
microcentrifuge tube, being careful not to transfer any of the Column Wash Solution with 
the Spin Column. If the Spin Column has Column Wash Solution associated with it, 
centrifuge again for 1’ at top speed, then transfer the Spin Column to a new, sterile 1.5 ml 
microcentrifuge tube. Add 100 μl of Nuclease-Free Water to the Spin Column. Centrifuge at 
top speed for 1’ at room temperature. Discard column, and store DNA at -20°C. 
DNA quantification by UV spectrophotometry 
Dilute 5 μl of sample in 1 ml of H2O into a quartz cuvette. Measure the absorbance at a 
wavelength of 260 nm and 280 nm by spectrophotometry. Absorbance (OD) of the sample 
at 260 nm provides a measure of the amount of nucleic acids present in the sample 
considering 1 OD=50μg/ml for DNA and 1 OD=40 μg/ml for the RNA, the absorbance at 280 
nm estimates the amount of protein contaminants. 
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PCR reaction 
DNA/cDNA 2.5 ng/μl 2μl 
Pfu (Promega) 1 μl 
dNTP 2mM 2μl 
Oligo forward + reverse mix 10μM 2μl 
Pfu Buffer 10x (Promega) 2μl 
H2O 11μl 
Final volume 20μl 
Amplification conditions are: 
1. 3’ 94°C 
2. 30’’ 94°C  denaturation, 
3. 30’’ at the specific annealing temperature of the primer 
4. 1’ at 72 °C per kb of DNA for the extension 
5. 10’ at 72°C 
Steps 2-3-4 are repeated for 30 cycles. 
 
Analysis of Intracellular and Extracellular Dopamine and Metabolites 
Intracellular and extracellular dopamine (DA), 3-methoxytyramine (3-MT), 3,4-
Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) were determined by 
HPLC with electrochemical detection as previously described (119). In brief, cells were 
lysed in 250 μL 1% metaphosphoric acid containing 1 μM EDTA. After centrifugation 
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(17,500 g for 10 min at 4°C), the supernatant was filtered, and a 15- μL aliquot was 
immediately injected into the HPLC system. In each experiment, 100 X 103 cells/cm2 were 
plated and treated 24 h later (time 0) with doxycycline 0.2 μg/mL. After 48 h, the medium 
was aspirated from each well and stored, and the cells were collected in metaphosphoric 
acid. Samples were subsequently analyzed for levels of total DA (DA+3-MT) and its 
metabolites DOPAC and HVA in cell lysates and incubation medium. Values in cell lysate 
were expressed as nanomoles per milligram of protein. Total cell extract protein 
concentration was determined using the method of Lowry et al. (1951). 
 
Capillary Tube Construction for in vitro Microdialysis 
The capillary tube for microdialysis of PC12 cell lines is an adaptation of an in vitro device 
described previously (120, 121). The microdialysis probe was constructed using two 
sections of plastic coated silica tubing (150 μm o.d., 75 μm i.d., Scientific Glass Engineering, 
Milton Keynes, UK), each placed in the centre of a semipermeable polyacrylonitrile dialysis 
fiber (AN-69, Hospal Industrie, Meyzieu, France). Each semipermeable membrane had an 
active length of 40 mm. Then each section of plastic-coated silica tubing was positioned in 
the centre of polyethylene tubing (0.58 mm i.d., 35 mm long, Portex). This section of silica 
tubing served as the inlet. Dialysates from polyacrylonitrile dialysis fiber were collected 
from polyethylene tubing, which served as the outlet. All parts were coated with quick-
drying epoxy glue. Afterwards the microdialysis probe (the semipermeable polyacrylonitrile 
dialysis fiber plus sealed plastic-coated silica tubing) was placed in non heparinized 
microhematocrit capillary tubes (7.5 mm long, 1.1 mm i.d., Chase Scientific Glass, 
Rockwood, IL, USA). The final volume of microdialysis chamber was approximately 50 μL. 
Microdialysis Procedures 
Microdialysis experiments were performed during the exponential phase of cell growth. 5 X 
104 cells/cm2 were plated and treated 24 h later (time 0) with different Doxycycline 
concentrations. After 48 h cells were washed twice using 5 ml of modified PBS and 10% 
DMEM (perfusion medium), harvested and centrifuged (94 g for 5 min). Cells were 
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resuspended in PBS/ DMEM and the number of cells/ml was assessed in a Burker chamber. 
The initial volume of the cell suspension was eventually adjusted to reach a final 
concentration of 1X106 cells/50 μL. Nicotine (5 mM) effect on DA secretion from PC12 lines 
was evaluated by means of microdialysis in vitro as previously described (121). The cellular 
microdialysis probe was perfused with PBS/DMEM by means of a peristaltic microinfusion 
double-channel pump (P720 peristaltic pump (Instech, Plymouth Meeting, PA, USA), which 
pumped PBS/DMEM at a flow rate of 3.0 μL/min. The pump channels were connected to 
the inlet by a length of polythene tubing. The perfusion apparatus was then filled with 50 
μL of the PC12 cell suspension by aspiration, which was performed manually by means of a 
1.0 mL syringe connected to the plastic coated silica tubing sealed outside the polythene 
tubing. Thereafter, the perfusion apparatus was kept at 37°C. After 1 h of stabilization, 3 
microdialysis samples (60 μL each) were recovered at 20 min intervals. Nicotine was added 
to the perfusion medium and removed after 60 min. In case of LRRK2 inhibitor treatments, 
GSK2578215A (1 μM) was added at the beginning of stabilization. Samples were recovered 
during the next two hours. Subsequently, a 35 μL aliquot of each collected dialysate was 
analysed by HPLC. The concentration of neurochemicals detected after the first 20 min of 
perfusion was taken as time 0 concentration. Cell viability was assessed before the start 
and at the end of each experiment by trypan blue exclusion. The viability rate was given as 
the difference between final and initial percentage of non-viable cells (120, 121). 
Chromatographic Analysis of Dialysates from PC12 Cell Suspension 
DA was quantified in dialysates of selected experiments (1.0 X 106 cells) by HPLC–EC, as 
described previously (120) using an Alltech 426 HPLC pump (Alltech, Sedriano, Italy) 
equipped with a Rheodyne injector (model 7725, Rohnert Park, CA, USA), a column (15 cm, 
4.6 mm i.d., ODS80TM C18, Toso Haas, Stuttgart, Germany), an electrochemical detector 
ANTEC– Leyden EC controller (ANTEC, Zoeterwoude, The Netherlands), and a PC-based 
ADC system (Varian Star Chromatographic Workstation, Varian, Walnut Creek, CA, USA). 
The mobile phase was citric acid (0.1 M), ethylenediaminetetraacetic acid (EDTA, 1.0 mM), 
methanol (8.7%) and sodium octylsulfate (48 mg/L), with a flow rate of 1.2 mL/min and pH 
2.9 
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Transient Transfections and Analysis of GH Secretion 
Transient transfection were performed with Lipofectamine LTX Reagent (Life Technologies) 
according to the manufacturer’s instructions. After an incubation of 4–6 h with transfection 
reagents, the cells were cultured in normal growth medium for 24 or 48 h. For GH secretion 
analysis, SH-SY5Y cells (1.0 X 105 cells) were seeded in 24 mm plates and co-transfected the 
following day either with GH-5Xmyc and pCS2-MTK empty vector or with GH-5Xmyc and 
the different pCS2-5Xmyc-LRRK2 isoforms in a ratio of 1:10. 24 hours after transfection, the 
cells were washed twice with fresh medium and normal growth medium was added for 
another 16 h. In case of LRRK2 inhibitor treatments, GSK2578215A was added 1 h before 
medium change and then after medium change. The extracellular medium was then 
collected and centrifuged at 10000xg for 10 min to eliminate cell debris, while the cells 
were washed twice with PBS and immediately lysed by Laemmli buffer 1X.  
For DRD1 membrane localization experiments, the cells were co-transfected in 6 cm plates 
as described above (in a ratio of 1:5 respectively for DRD1-3Xflag and 5Xmyc-LRRK2 or 
empty vector) for 48 hours. The quantification of either GH-5Xmyc or DRD1-3Xflag in the 
different fractions was performed by western blot analysis and densitometric evaluation of 
the obtained bands (Quantity-One Biorad). 
Subcellular Fractionation of Cells or Mouse Tissues 
Tissues from 2 months old LRRK2 WT or LRRK2 G2019S transgenic mice [16] were quickly 
dissected and frozen. Subcellular fractionation was conducted as described in (100). Briefly, 
SHSY5Y or HEK293 cells or striatum were homogenized in ice-cold homogenization-buffer 
(320 mM sucrose, 4 mM HEPES, pH 7.4, protease inhibitor cocktail from Sigma). The 
homogenates were centrifuged at 1000 X g for 10 min to produce the pellet containing 
nuclei and large debris fraction (P1). The supernatant (S1) was further fractionated into 
pellet (P2 containing the membrane fraction) and supernatant (S2) by centrifugation at 
10,000 X g for 20 min. The S2 was ultracentrifuged at 100,000 X g to obtain the pellet (P3 
containing the vesicle fraction). Protein content was determined using the Bradford protein 
assay. Equal amount of protein extracts were loaded into the SDS-PAGE. 
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SDS PAGE and Western immunoblotting 
Protein content was determined using the Bradford protein assay. Equal amount of protein 
extracts were resolved by standard SDS/PAGE. Samples were electroblotted onto Protan 
nitrocellulose (Schleicher & Schuell GmbH). Membranes were incubated with 3% low-fat 
milk in 1 X PBS-Tween 0.05% solution with the indicated antibody for 16 h at 4°C. Anti-
Rabbit IgG (whole molecule)- and Anti-Mouse IgG (whole molecule)-Peroxidase antibody 
were used to reveal immunocomplexes by enhanced chemioluminescence (Pierce). 
 
EGF-R internalization assay  
SH-SY5Y cell lines were cultured in Dulbecco’s modified Eagle’s medium containing 15% 
Foetal bovine serum, 1% MEM NEAA, gentamicin. For cell lines co-expressing a blasticidin 
selection marker, growth medium was supplemented by blasticidin 10 µg/ml (Invivogen, 
San Diego, CA, USA). The cells are cultured for 16 hours in serum free medium and then 
incubated with medium containing 100 ng/ml fluorescently labelled Rhodamine-
conjugated EGF (EGF-Rh) at 37°C. Cells are then washed two times with PBS 1X to remove 
excess labelled EGF and fixed in formaldehyde 4% w/w in PBS for the time points indicated 
in the result section (0-30 minutes). Cells were imaged by confocal microscopy with an 
Olympus FV1000 microscope. Imaged cells were scored for co-localization of LRRK1 or 
LRRK2 with EGF-Rh positive endosomes. Cells with at least 5 double positive endosomes 
are scored as positive. For each condition tested, at least 3 wells with 20-100 cells per well 
were scored. 
Statistical analysis 
All quantitative data are expressed as means ± SEM, all experiments were performed in 
triplicate or better. 
Concentrations of neurochemicals in dialysates from PC12 cell suspension were expressed 
in μM and given as mean ± SEM. Drug effects on neurochemicals were statistically 
evaluated in terms of changes in absolute dialysate concentrations. Differences within or 
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between groups were determined by paired or unpaired t-tests (ANOVA followed by 
Student–Newman–Keuls post-hoc analysis). The null hypothesis was rejected when p < 
0.05. 
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3.1 Characterization of PC12 Cells Stably Expressing Doxycycline-inducible LRRK2 WT or 
Pathological Mutants (in collaboration with the Department of Clinical and Experimental 
Medicine – University of Sassari)  
For the  microdialysis experiments described below a PC12-TET-ON cell line (Clontech 
Laboratories Inc) or PC12-TET-ON cell lines expressing the plasmid pTRE2 containing the 
cDNAs coding for LRRK2 variants (WT or R1441C or G2019S) were used.  
The TET-ON System allows the inducible expression of LRRK2 variants coded in the pTRE2 
plasmid and is shown in figure 14. The TET-ON system utilizes doxycycline, a tetracycline 
analogue, to induce transcription. When Doxycycline is added into the cell medium, the 
transactivator, (already stably expressed in TET-ON cells), is engaged in a conformational 
change allowing it to bind the tetracycline response elements (TRE) which in turn leads to 




In particular in the PC12 cell lines used in this work express the “tet reversed activator 
system” in which a tetracycline repressor mutant is fused with the Herpes Simplex VP16 
activation domain thus acting as a transactivator.  
To generate the PC12-ON stable line, plasmid constructs for wild type LRRK2 or for 
pathological mutants LRRK2 G2019S and LRRK2 R1441C were transfected in PC12-ON cell 
lines. After several weeks of selection by hygromicin, single stable clones were isolated. 
Different clones were characterized and finally three clones expressing comparable level of 
Figure 14: The TET-ON expression system. 
LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
63 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 
Studi di Sassari 
LRRK2 protein after 48 h of induction by 0.2 g/ml doxycycline treatment were chosen 
(Figure 15 A upper panel). All cell lines expressed comparable levels of Tyrosine 
Hydroxylase (TH) after the same treatments (Figure 15 A, middle panel). A higher dose of 
doxycycline (1 g/mL) does not further increase the LRRK2 expression level (Figure 15 B). 





Once established the expression homogeneity of the different LRRK2, the dopamine and 
dopamine metabolites levels in the different clones were assessed in basal growth 
conditions. 48 hours after 0.2 g/ml doxycycline treatment, the intracellular and 
extracellular dopamine (DA) level and its metabolism products were analyzed in the 
different cell lines (Figure 16). All the stable clones show comparable intracellular and 
extracellular levels of DA content as well as the intracellular and extracellular level of 
DOPAC+HVA, allowing the comparative analysis between the different stable clones 
performed in the following experiments. 
Figure 15. Characterization of PC12 cell expressing WT or mutant LRRK2. (A) PC12-derived cells 
expressing myc-tagged human WT or mutant-LRRK2 were left untreated (-) or treated (+) for 48 h 
with 0.2 μg/mL doxycycline to induce expression of transgenic LRRK2. Cell lysates were subjected 
to reducing SDS/PAGE. The anti-myc antibody was used to visualize LRRK2 and anti-TH for 
tyrosine hydroxylase. β-actin serves as controls for equal loading of samples. (B) Dose dependent 
expression of doxycyline-inducible LRRK2 G2019S. Cells were treated for 48 h with the indicated 
concentration of doxycycline and equal amounts of protein were tested in Western blot analysis 
with anti-myc or anti-β-actin antibodies 
LRRK2 – an important player in Parkinson’s Disease – role in vesicle and receptor trafficking 
64 
Del Giudice Maria Grazia: “LRRK2 – an important player in Parkinson’s Disease – role in vesicle and 
receptor trafficking”. Scuola di Dottorato in Scienze Biotecnologiche e Biomeolecolari – Università degli 





3.2 LRRK2 Influences the Basal and Nicotine-induced secretion of DA in PC12 Cells (In 
collaboration with the Department of Clinical and Experimental Medicine – University of 
Sassari) 
In order to evaluate the effect of the expression of LRRK2 on basal and nicotine-induced 
secretion of DA, a microdialysis study was performed on the PC12 cell model [33] treated 
with 0.2 g/mL doxycycline for 48 h compared with untreated (2) cells. This doxycycline 
dose was chosen because, in preliminary experiments, it did not show any significant effect 
on DA secretion on PC12-ON cells in contrast to 1 g/mL of doxycycline that had a negative 
effect on DA secretion. Microdialysates were collected at 20 minute intervals after 1 h of 
stabilization (Figure 17 A–B–C–D). The time course analysis of basal and nicotine induced 
dopamine release in the absence (Figure 17 A) or presence (Figure 17 C) of doxycycline is 
shown. In Figure 17 B–D, the Area Under Curve (AUC) of the different samples is shown; in 
particular, the baseline of DA+3-MT is represented from the AUC of points 20–60 minutes 
before nicotine treatment in absence. (Figure 17 B bars) or presence of doxycycline (Figure 
17 B barred bars), while the DA+3-MT nicotine-induced release is represented by the AUC 
related to points 80–220 minutes in absence (Figure 17 D black bars) or presence of 
doxycycline (Figure 17 D dotted bars). The expression of LRRK2 G2019S induces an 85% 
Figure 16. Characterization of PC12 cell expressing WT or mutant LRRK2. Effect of doxycycline 
on DA and DOPAC+HVA concentration in PC12 cells lysates and extracellular medium after 48 h 
expression. At the beginning of each experiment, 105 PC12 cells/cm2 were plated and after the 
desired incubation period, the medium was aspirated from each well and stored, and the cells 
were collected in metaphosphoric acid. Samples were subsequently analyzed for levels of DA and 
its metabolites DOPAC and HVA in cell lysates and incubation medium. Results are the means ± 
SEM of three experiments performed in triplicate. 
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increase (p<0.05) vs corresponding control in the basal level of total extracellular DA 
(DA+3-MT), as shown in figure 17 C (20–40–60 minutes) compared to 17 A (20–40–60 
minutes) and quantified by the AUC in Figure 17 B. In contrast, under the same 
experimental conditions expression of either LRRK2 WT or LRRK2 R1441C does not induce a 
significant increase in total DA extracellular levels (Figure 17 A–C and quantified in 17 B). 
Interestingly, the presence of mutant LRRK2 determines an increase in nicotine-induced DA 
compared to PC12-ON or LRRK2 WT cells (Figure 17 C 60–220 minutes vs 17 A 60–220 
minutes). Quantification by AUC of secreted DA indicates an increase of 22% (although not 
statistical significant) and 61% (p<0.05), respectively for LRRK2 R1441C and LRRK2 G2019 
(Figure 17 D). Under the same experimental conditions, were measured extracellular levels 
of DOPAC+HVA. A significant change both in the basal condition and after nicotine infusion 
is observed following doxycycline treatment in PC12 cells expressing LRRK2 WT or LRRK2 R1441C 
(Figure 18 A–B–C–D). In particular the values are 261.4% for WT and 251.7% for LRRK2 R1441C in 
doxycycline treated samples and 264.9% for WT and 245.3% for R1441C mutant by doxycycline and 
nicotine treatment. No significant differences were observed in PC12-ON cells or expressing 
the LRRK2 G2019S mutant. To evaluate the importance of LRRK2 kinase activity on 
increased DA extracellular level, we used the LRRK2 inhibitor GSK2578215A on PC12-ON or 
PC12-ON expressing the LRRK2 G2019S. The presence of LRRK2 inhibitor does not influence 
the DA extracellular level in basal conditions (20–40–60 minutes in figure 19 A vs B or the 
relative AUC in Figure 19 C) in both cellular types. In presence of nicotine, the inhibitor 
does not affect the expected increase in DA extracellular level in PC12-ON cells while it 
determines a reduction in PC12-ON expressing the LRRK2 G2019S mutant although this DA 
extracellular level decrease does not rich statistical significance in three independent 
experiments (Figure 19 A from 60 to 220 minutes vs 19 B from 60 to 220 minutes and the 
relative AUC in Figure 19 D). Under the same experimental conditions, the GSK2578215A 
inhibitor does not affect the concentration of DOPAC+HVA. 
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Figure 17. Effect of LRRK2 expression on dopamine (DA+3-MT) extracellular level. PC12-derived 
cell lines were left untreated (A) or treated (C) for 48 h with 0.2 μg/mL doxycycline. After 60 
minutes of stabilization, three baseline dialysates were collected at 20-minute intervals [gray bars 
in panel (A), and gray bars with stripes in panel (C)]. Starting from 60 minutes, nicotine was 
infused for 60 minutes (capped lines). Microdialysates wer continuously recovered during drug 
infusion and after nicotine discontinuation [black bars in panel (A), and dotted bars in panel (C)]. 
Values are mean ± SEM and refer to dopamine concentrations in dialysates. Statistical 
significance was assessed using analysis of variance (ANOVA) for differences over time 
determined by Newman-Keules t test and unpaired t-tests. *p < 0.05 compared with pertinent 
baseline values of all groups. Graphs in panel (B) and (D) represent the area under curve (AUC) 
values. (B) Basal dopamine concentration in dialysates of PC12 cell lines untreated (gray bars 
corresponding to the same color in panel A) or treated with 0.2 μg/mL doxycycline [gray bars 
with stripes corresponding to same color in panel (C)]. (D) Dopamine concentrations in dialysates 
integrated after nicotine administration in PC12 cell lines untreated [black bars corresponding to 
same color in panel (A)] or treated with 0.2 μg/mL of doxycycline [dotted bars corresponding to 
same color in panel (C)]. AUC values are mean ± SEM. *p < 0.05 vs corresponding control. 
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Figure 18. Effect LRRK2 expression on DOPAC+HVA concentrations. PC12-derived cell lines 
were left untreated (A) or treated (C) for 48 h with 0.2 g/ml doxycycline. After 60 minutes of 
stabilization, three baseline dialysates were collected at 20-minute intervals [bars in panel (A), 
and grey bars with stripes in panel (C)]. Starting from 60 minutes, nicotine was infused for 60 
minutes (capped lines). Microdialysates were continuously recovered during drug infusion and 
after nicotine discontinuation [black bars in panel (A), and dotted bars in panel (C)]. Values are 
mean ± SEM and refer to DOPAC+HVA concentrations in dialysates. Statistical significance was 
assessed using analysis of variance (ANOVA) for differences over time determined by Newman-
Keules t test and unpaired t-tests. *p < 0.05 compared with pertinent baseline values of all 
groups. Graphs in panel (B) and (D) represent the area under curve (AUC) values. (B) Basal 
DOPAC+HVA concentration in dialysates of PC12 cell lines untreated [bars corresponding to the 
same colour in panel (A)] or treated with 0.2 g/mL doxycycline [bars with stripes corresponding 
to the same colour in panel (C)]. (D) DOPAC+HVA concentrations in dialysates integrated after 
nicotine administration in PC12 cell lines untreated [black bars corresponding to the same 
colour in panel (A)] or treated with 0.2 g/ml doxycycline [dotted bars corresponding to the 
same color in panel (C)]. AUC values are mean ± SEM. *p < 0.05 vs corresponding control. 
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Figure 19: Effect of LRRK2 inhibitor GSK2578215A on dopamine (DA+3-MT) extracellular level. 
PC12-derived cell lines were left untreated (A) or treated (B) by 1 μM of GSK2578215A. After 60 
minutes of stabilization, three baseline dialysates were collected at 20-minute intervals as 
previously described. Starting from 60 minutes, nicotine was infused for 60 minutes. Values are 
mean ± SEM and refer to dopamine concentrations in dialysates. Statistical significance was 
assessed using analysis of variance (ANOVA) for differences over time determined by Newman-
Keules t test and unpaired t-tests. *p < 0.05 compared with pertinent baseline values of all 
groups before nicotine treatment. Graphs in panel (C) and (D) represent the area under curve 
(AUC) values. (C) Basal dopamine concentration in dialysates of PC12 cell lines untreated or 
treated with 1 μM of GSK2578215A (minutes 20–40–60 before nicotine treatment of Figure 19 
A vs B). (D) Dopamine concentrations in dialysates integrated after nicotine administration in 
PC12 cell lines untreated or treated with 1 μM of GSK2578215A (from minutes 80 to 220 after 
nicotine treatment of Figure 19 A vs B). AUC values are mean ± SEM. 
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3.3 Vesicle Distribution in PC12 Cells Expressing LRRK2 G2019S Pathological Mutant 
Results obtained on dopamine extracellular levels changes associated with LRRK2 
expression prompted to understand whether LRRK2 might be involved in synaptic vesicle 
(SV) movement/distribution. 
The vesicles distribution in PC12-ON or PC12-ON-LRRK2 G2019S cell lines was studied using 
an electron microscopy approach. Expression was induced for 24 hours with 0.2 g/mL 
doxycycline and cells were quickly fixed for electron microscopy. Non-induced cells served 
as a control. Analysis of SV dimensions or relative abundance did not show significant 
differences between the different groups. Conversely LRRK2 expression seemed to 
influence synaptic vesicle distribution in terms of shorter distance to the plasma 
membrane. Namely it is displayed a clear increase in the relative abundance of vesicles 
located in close proximity to the membrane in presence of LRRK2 G2019S mutant 
compared to the same cells not expressing the mutant or to PC12 ON cells either treated or 
untreated with doxycycline (Figure 20 A–B). The level of LRRK2 expression in the different 
cell lines was analyzed by Western blot using an aliquot of cells before fixation and it is 
shown in Figure 20 C. 
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Figure 20: Effect of LRRK2 
G2019S expression on 
vesicle distribution.  
Transmission electron 
micrographs of PC12-ON 
or PC12-LRRK2 WT or 
PC12-LRRK2 G2019S cells 
untreated (-) or treated 
with 0.2 g/ml 
doxycycline for 48 h (+). 
Arrows point at vesicles 
near the membrane. N 
indicates the nucleus. 
Scale bars = 0,5 μm (B) 
Quantification of data in 
the panel. Bars represent 
the mean ± SEM (n = 30 
cells/sample). **p < 0.01 
comparing cells expressing 
or not LRRK2 G2019S as 
indicated. (C) Control 
Western blot analysis 
using anti-myc (to detect 
LRRK2) and anti-β-actin 
(as loading standard) on 
cells treated as in (A). 
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3.4 LRRK2 Increases Growth Hormone Extracellular Level in Neuronal Cells 
To further evaluate the involvement of LRRK2 in the mechanisms of vesicle trafficking a 
plasmid construct to follow secreted proteins was used. This construct consists of mouse 
growth hormone (mGH), containing a myc-tag at the C-terminal position. GH secretion has 
been largely used to follow neuronal secretion, since GH is localized predominantly in 
vesicles in regulated secretory pathways [34,35]. mGH was co-transfected alone or 
together with different LRRK2 constructs in both neuronal in SH-SY5 or non-neuronal 
(HEK293) cells. 24 h after co-transfections the cell medium was changed and the level of 
GH secretion was evaluated collecting the extracellular medium 16 h later. As shown in 
figure 21 A, the presence of LRRK2 WT in SH-SY5Y determines a slight increase in 
extracellular GH level. This level is further increased in the presence of mutant LRRK2, with 
LRRK2 G2019S inducing the maximum effect (Figure 21 A–E). Total cell lysates were used to 
analyze the intracellular level of mGH, LRRK2 and β-actin as control for homogeneity of 
transfection efficiency and protein amount loading (Figure 21 A). Interestingly, the effect of 
LRRK2 on GH secretion was not visible performing similar experiments in kidney HEK-293 
cells (Figure 21 B–E) suggesting a possible neuronal-specific mechanism of action for 
LRRK2. In order to understand the role of LRRK2 kinase activity in the control of GH 
extracellular level two different approaches were used. First, we analyse the effect of two 
LRRK2 dead kinase mutants carrying a deletion (delta-kinase) or point mutation (D1994A). 
Surprisingly, the absence of kinase domain completely abolishes the LRRK2 effect on GH 
extracellular level, while LRRK2 D1994A has an effect roughly comparable to LRRK2 WT 
(Figure 21 C).  And secondly, to further evaluate the importance of LRRK2 kinase activity we 
used the LRRK2 inhibitor GSK2578215A. The presence of LRRK2 inhibitor significantly 
reduces the increase in GH extracellular level due to LRRK2 G2019S expression (Figure 21 
D–F). 
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Figure 21. Effect of LRRK2 expression on released GH from neuronal and non-neuronal cells. (A) 
SH-SY5Y were transfected with plasmids coding for GH alone (-) or with the indicated mutant 
LRRK2s. Western blot on the extracellular medium (released GH) or cell protein extracts were 
performed using anti-myc antibodies for GH or LRRK2 and anti-β-actin as controls for equal loading 
of samples. The asterisk (*) indicates a nonspecific band. (B) HEK293 cells were transfected with GH 
alone (-) or with LRRK2 G2019S. Western blot on the extracellular medium (released GH) or cell 
protein extracts were performed using Anti-myc antibody for GH or LRRK2 and anti-β-actin as 
controls for equal loading of samples. The asterisk (*) indicates a non-specific band. (C) Analysis of 
LRRK2 D1994A or LRRK2 Δ kinase on GH extracellular level in the same experimental conditions. (D) 
Effect of LRRK2 inhibitor on GH extracellular level in the same experimental conditions (E) 
Quantification by Student’s t test of data obtained in (A–B–C). **p < 0,01 and ***p < 0,001 versus 
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3.5 LRRK2 Affects the Localization of Dopamine Receptor D1 both in Neuronal Cells and 
Transgenic Mouse Tissues 
Vesicle trafficking is a complex process regulating multiple different cellular functions, 
including neurotransmitter or protein release and localization of membrane receptors. The 
previous results prompted the analysis of  the possible effect of LRRK2 on membrane 
receptor localization using the membrane levels of dopamine receptor D1 (DRD1) as a 
read-out. DRD1 is highly expressed in the prefrontal cortex, striatum and nucleus 
accumbens, although it is absent in dopaminergic cells where Dopamine D2 receptors 
(DRD2) are expressed(122). SH-SY5Y cells were co-transfected with plasmid coding for 
DRD1 in absence or in presence of one among LRKK2 WT, LRKK2 G2019S, LRKK2 R1441G, 
LRKK2 D1994A or LRKK2 Δ kinase. 48 hours after transfection, the sub-cellular distribution 
of DRD1 receptors was analysed by cell fractionation. As shown in figure 22, the presence 
of LRRK2 G2019S and LRKK2 R1441G, and, to a lesser extent, of LRRK2 WT or LRRK2 
D1994A determines a significant increase in the level of membrane-associated DRD1 
compared to controls with DRD1 alone, while the effect is completely abolished in 
presence of LRKK2 delta-kinase. In agreement with previous findings on GH secretion, this 
effect is not observed in HEK293 cells (Figure 22 B). To extend the analysis to in vivo 
models the distribution of two neurotransmitter receptors was analyzed in the striatum of 
transgenic LRRK2 G2019S mice compared to non-transgenic mice. In particular, was 
compared the distribution of NMDA-NR1 receptor (NR1) and DRD1 in total, membrane or 
vesicle fractions obtained from the striatum of 5 different animals of the two genotypes. 
The samples were independently prepared, quantified and pooled together before SDS-
PAGE loading using the same amount of protein. As shown in Figure 23 A the expression of 
LRRK2 G2019S leads to a significant increase of DRD1 in membrane fraction paralleling a 
significant decrease in vesicle fraction, with no significant differences in total protein 
extracts between the two genotypes (Figure 23 B). No significant differences in the 
different fractions were observed for NR1, clathrin or sec8, a member of the exocyst 
complex. 
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Figure 22. Effect of LRRK2 on Dopamine D1 receptor (DRD1) distribution on neuronal and non-
neuronal cells). A) SH-SY5Y or HEK293 were transfected with DRD1 alone (-) or with the indicated 
mutant LRRK2. Western blot on the total and membrane fraction proteins were performed using 
anti-flag antibody for DRD1 or anti-myc for LRRK2 and anti-β-actin or clathrin as controls for 
equal loading of samples. Note that for SDS-PAGE analysis the protein samples were not boiled as 
suggested in anti-DRD1 data sheet. (B) Quantification by Student’s t test of data obtained in (A). 
*p < 0,05 **p < 0,01 and ***p < 0,001. 
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Figure 23. Effect of LRRK2 on Dopamine D1 receptor (DRD1) distribution on the striatum of 
G2019S LRRK2 or non-transgenic mice. The total, membrane or vesicle fractions were purified 
from 5 different LRRK2 G2019S transgenic mice or relative control (Non-Tg). Each of the five 
fractions were quantified and pooled together. A) Analysis of DRD1 level on protein extracts from 
membrane or vesicle fraction obtained from striatum of Non-Tg or LRRK2 G2019S transgenic mice. 
The western blot was performed using anti-DRD1, anti-NR1, anti-Sec8, or anti-clathrin antibodies. 
Note that for DRD1 analysis the samples were not boiled for the SDS-PAGE analysis as 
recommended in the antibody data sheet. B) Analysis of DRD1 level on total protein extracts 
obtained from striatum of Non-Tg or LRRK2 G2019S transgenic mice. The western blot was 
performed using anti-DRD1, anti-actin or anti-clathrin antibodies. Note that for DRD1 analysis the 
samples were not boiled for the SDS-PAGE analysis. 
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3.6 LRRK1 and LRRK2 functional redundancy in receptors trafficking 
Epidermal growth factor treatment induces translocation of LRRK1, but not LRRK2, to 
endosomes. 
To assess a potential cross-talk between LRRK1 and LRRK2 in respect to EGF receptor 
(EGFR) trafficking pathway a combination of four different cell lines derived from SH-SY5Y 
cells was used. Namely stably SH-SY5Y cells generated by co-transduction of a LRRK1 
knockdown (KD) or KD control construct and a full-length eGFP-LRRK2 construct, or 
alternatively, a LRRK2 KD or KD control construct and full-length eGFP-LRRK1 construct. A 
western blot displaying LRRK1 and LRRK2 expression levels in control and knockdown cell 
lines is showed in figure 24. The combination of cell lines used for the experiments here 
described is represented in the scheme below, the lentiviral (LV) construct names in 





The four different SH-SY5Y used in the following experiments 
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LRRK1 has previously been shown to translocate to endosomes upon treatment of HeLa 
cells with EGF (117). This occurs through activation of the endogenous EGF receptor 
(EGFR), which is also expressed endogenously in SH-SY5Y cells (123). To confirm the LRRK1 
EGF-induced translocation in neuronal cells, SH-SY5Y cells stably expressing eGFP-LRRK1 
and a knock-down control construct (knockdown construct targeting the firefly luciferase 
gene) were treated with Rhodamine-conjugated EGF (EGF-Rh) at 100 ng/ml for 5, 15 or 30 
minutes in order to mark EGFR positive endosomes. LRRK1 is recruited to EGFR positive 
endosomes assuming a punctate pattern (see figure 25) while upon the same EGF-Rh 
stimulation SH-SY5Y-eGFP-LRRK2 stable lines do not show any change in LRRK2 localization 
(figure 26 and 30-a). Statistical significance of these observations was confirmed by a two 
way ANOVA analysis:  all the experiments have been performed in triplicate and imaged 
cells were scored for co-localization of LRRK1 or LRRK2 with EGF-Rh positive endosomes. 
Cells with at least 5 double positive endosomes were scored as positive. For each condition 
tested, at least 3 wells with an average of 84 cells per well were scored. Two way ANOVA 
Figure 24: Western blot showing LRRK1 and LRRK2 expression levels in control and knockdown 
cell lines. The cell lines were obtained co-transducing SH-SY5Y cells with lentiviral vectors 
expressing eGFP-LRRK2 or eGFP-LRRK1 and the short hairpin RNA (microRNA based) vectors 
respectively for LRRK1 or LRRK2 knockdown or knockdown control vectors targeting the fire 
luciferase (Fluc) sequence. (The number immediately following the gene name refers to the 
position on the cDNA sequence of the first base of the short hairpin sequence).  
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Figure 25: EGF induced translocation of LRRK1. Confocal laser scanning micrographs of SH-SY5Y 
stably expressing eGFP-LRRK1: untreated (t=0’) or treated with 100 ng/mL EGF-Rhodamine 
conjugate for 5, 15 and 30 minutes. EGF-Rh internalized by the cells is visible as red punctate 
pattern corresponding to endosomal structures. EGF treatment induces GFP-LRRK1 
translocation in punctate structures in the cytoplasm which co-localizes with EGF-Rh positive 
endosomes.  Scale bar, 10 µM applies to all photomicrographs.  
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Figure 26: EGF does not induce translocation of LRRK2. Confocal laser scanning micrographs  
of SH-SY5Y stably expressing eGFP-LRRK2  untreated (t=0’) or treated with 100 μg/mL EGF-
rhodamine conjugate  for 5, 15 and 30 minutes. EGF-Rh is internalized by the cells showing a 
red punctate pattern but any translocation of GFP-LRRK2 is observed at any EGF-Rh treatment 
time-point.  Scale bar, 10 µM applies to all photomicrographs.  
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As LRRK1 has been reported to interact with LRRK2 (113, 124), I tested whether LRRK2 was 
required for the recruitment of LRRK1 to endosomes. For this, cells stably expressing eGFP-
LRRK1 and LRRK2 KD (LV_miR_LRRK2_6251) were treated with EGF-Rh 100 ng/ml.  The EGF 
induced LRRK1 recruitment to endosomes was comparable in the presence of LRRK2 
knockdown compared to control cell lines (Figure 28 and Figure 30 panel b).  
Lastly, to assess whether LRRK2 was able to supply LRRK1 function in EGFR trafficking I 
used stable expressing eGFP-LRRK2 and LRRK1 KD (LV_miR_LRRK1_6734) treating them as 
previously described with EGF-Rh. As shown in figure 29  figure 30 (panel b) LRRK2 is 
neither recruited to EGF-Rh positive endosomes or changing distribution pattern in a LRRK1 
knock-down background. 
To assess whether differences between the various conditions analyzed had statistical 
significance a two way ANOVA analysis was performed. All the experiments have been 
performed in triplicate and imaged cells were scored for co-localization of LRRK1 or LRRK2 
with EGF-Rh positive endosomes. Cells with at least 5 double positive endosomes were 
scored as positive. For each condition tested, at least 3 wells with an average of 84 cells per 
well were scored. As summarized in figure 27, differences between GFP-LRRK1 + KD control 
and GFP-LRRK1 + LRRK2 KD group, or GFP-LRRK2 + KD control and GFP-LRRK2 + LRRK1 KD 
Table 5: Two way ANOVA results. Comparison between GFP-
LRRK1 control and GFP-LRRK2 control cell lines treated with EGF-
Rh 100 ng/ml for 5, 10, 15 or 30 minutes or untreated (0 min). 
Significance is indicated with *. 
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group have no statistical significance, thus KD of LRRK2 does not influence LRRK1 
recruitment to EGF-Rh positive endosomes and vice versa KD of LRRK1 does not influence 












Figure 27: Two away ANOVA analysis of confocal 
images: KD of LRRK2 does not influence LRRK1 
recruitment to EGF-Rh positive endosomes and vice 
versa KD of LRRK1 does not influence LRRK2 behavior 
in the same conditions. Differences between GFP-
LRRK1 (KD control) and GFP-LRRK1/LRRK2 KD (refer to 
upper table) or GFP-LRRK2 (KD control) and GFP 
LRRK2/LRRK1 KD (refer to lower table) are not 
statistical significant.   
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Figure 28: EGF does induce LRRK1 translocation in a LRRK2-KD background. Confocal laser 
scanning micrographs  of SH-SY5Y stably expressing eGFP-LRRK1 + KD LRRK2  untreated (t=0’) 
or treated with 100 μg/mL EGF-rhodamine conjugate  for 5, 15 and 30 minutes. EGF-Rh is 
internalized by the cells showing a red punctate pattern co-localizing with GFP-LRRK1 puncta. 
Scale bar, 10 µM applies to all photomicrographs.  
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Figure 29: EGF does not induce translocation of LRRK2 in a LRRK1-KD background. Confocal 
laser scanning micrographs  of SH-SY5Y stably expressing eGFP-LRRK2 + KD LRRK1  untreated 
(t=0’) or treated with 100 μg/mL EGF-rhodamine conjugate  for 5, 15 and 30 minutes. EGF-Rh is 
internalized by the cells showing a red punctate pattern but any translocation of GFP-LRRK2 is 
observed at any EGF-Rh treatment time-point.  Scale bar, 10 µM applies to all 
photomicrographs.  
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Figure 30--a: EGF induces LRRK1 but not LRRK2 translocation.. Confocal laser 
scanning micrographs  of SHSY-5Y stably expressing eGFP-LRRK1 and eGFP-LRRK2 
are compared.  Untreated condition is indicated as t=0’ and compared with 30 
minutes treatment with EGF-rhodamine  100 ng/ml.  Scale bar, 10 µM.  
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 Figure 30—b: LRRK2 is not required for EGF-Rh induced LRRK1 translocation. 
Scale bar, 10 µM.  
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Table 6. Two way ANOVA result tables 
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 In neurons, vesicle trafficking mediates neurotransmitter or protein release and uptake, 
localization of membrane receptors, changes in plasma membrane composition at the cell 
surface and, not least, organelle biogenesis, thus underlying virtually all functions of the 
nervous system. The transport, binding and fusion of secretory vesicles with the cell 
surface are tightly regulated and their dysregulation has been implicated in PD and other 
neurological disorders(125).  
There are two exocytosis pathways, constitutive and regulated, by which secretory proteins 
are released from cells. Regulated exocytosis is triggered by signals originating outside the 
cell, usually through a rise in Ca2+ concentration at release sites; however, the regulated 
pathway also exhibits basal or unstimulated secretion, which is distinct from constitutive 
secretion (126). 
 Moreover, there is now a general consensus that synaptic vesicles formation relies 
predominantly on the endocytic pathway (127) strongly suggesting a prominent role of 
endocytosis in the control of neurotransmitter extracellular level or membrane receptor 
level. 
 Neurons and neuroendocrine cells (for example, PC12 cells) have both constitutive and 
regulated exocytosis, while most non-neuronal cells have only constitutive secretion. 
Chromaffin PC12 cells have been extensively used as cellular model of dopaminergic 
neurons to study vesicle trafficking under basal or stimulated conditions (128). In fact, PC12 
cells mimic many features of central DA neurons; they are characterized by the presence of 
catecholamine synthesizing enzymes (i.e. tyrosine hydroxylase) (129), catecholamine 
storage granules of about 0.2–0.5 mm (129, 130) and DA receptors, as well as by DA uptake 
mechanisms. Like dopaminergic neurons, PC12 cells also contain the type A isoform of 
monoamine oxidase (MAO) (131). Finally, the microdyalisis results presented in this work  
and previous results from other groups have demonstrated that PC12 cells release 
catecholamines in response to different stimulations (121, 132). Moreover, PC12 cells 
together with SH-SY5Y neuronal cells have been largely used to analyze the LRRK2 physio-
pathological functions (75, 76, 133, 134).  
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This research highlights an important cellular function of LRRK2 in the regulation of vesicle 
trafficking. Using different experimental approaches is demonstrated that the presence of 
PD-linked mutant LRRK2 determines an increase in DA extracellular level in short-time 
dynamic experiments in PC12 cells, an increase in GH release in SH-SY5Y cells and an 
increase of DRD1 on cell membrane of both SH-SY5Y cells and striatum of LRRK2 G2019S 
transgenic mice. Moreover a functional redundancy study performed by an ad hoc 
designed immunocytochemistry assay demonstrates that LRRK2 is not involved in the 
control of EGF receptor trafficking whereas its homologue LRRK1 does, providing clues to 
define which pathway or pathways could involve LRRK2 and be linked with 
neurodegeneration in PD.    
The content of intracellular DA, DOPAC and HVA and DA, 3-MT, DOPAC and HVA in culture 
medium is similar in all the LRRK2-containing clones, whether or not expression of the 
protein has been induced (Figure 16). This result suggests that LRRK2 expression does not 
interfere with basal dopamine metabolism. An alternative explanation is that long time 
sampling of extracellular content (48 h) may mask small/significant differences in DA 
secretion and metabolism among different PC12 clones since catecholamine medium 
content is the result of several biological phenomena including secretion, reuptake and 
enzymatic oxidative metabolism, but as well as the outcome of chemical events such as 
autoxidation of hydroxyl groups (121). However, short-time dynamic experiments 
performed using in vitro microdialysis demonstrate a basal increase of DA secretion in cells 
expressing LRRK2 G2019S and a nicotine induced increase of extracellular DA in those 
expressing both mutated LRRK2 genes (Figure 17 A–B). Interestingly, these results on PC12 
cells match that of LRRK2 G2019S transgenic rat model (135), in which temporally induced, 
but not constitutive, overexpression of LRRK2 G2019S determines an increased DA 
extracellular level and an increased motor activity, probably due to an impairment in 
dopamine reuptake by dopamine transporter (135). 
 In our PC12 cells, LRRK2 expression negatively affects the DA enzymatic metabolism, 
resulting in a decrease of DOPAC+HVA in basal microdialysate samples with the exception 
of the LRRK2 G2019S cells and the same trend is emphasized by nicotine treatment. This 
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difference may be explained by the increased DA secretion in LRRK2 G2019S  expressing 
cells with the consequent reuptake and rise of the substrate available for intracellular 
MAO-A enzymes. 
The expression of LRRK2 G2019S also affects the vesicle distribution in PC12 cells in terms 
of shortest distance from cell membranes. Although the ultrastructural analysis does not 
discriminate univocally the three different SV classes (136), it has generally been assumed 
that the vesicles closest to release sites (in a range of 100 nm) and the docked vesicles 
represent the readily releasable pool (RRP) and thus are recruited first during synapse 
activity (137). Moreover it has been shown that the electrophysiological properties as well 
as the proper vesicular trafficking and spatial distribution in the presynaptic pool depend 
on the presence of LRRK2 as an integral part of presynaptic protein complex (97). Thus, 
electron microscopy results may suggest that the increase in extracellular DA level either in 
basal conditions or after nicotine stimulation may be due to alteration in vesicle 
distribution inside the cells. Strikingly, an increased DA turnover has been noticed in 
presymptomatic LRRK2 mutation carriers (138). It has been suggested that increased DA 
turnover might by itself contribute to disease progression secondary to DA associated 
toxicity  (139, 140). A role for LRRK2 as presynaptic scaffold protein regulating vesicle 
trafficking and indirectly DA turnover, as suggested by our results, fits perfectly in this 
picture. The increase in DA level in the extracellular medium of PC12 expressing LRRK2 
G2019S is comparable to the biological effect detectable in SH-SY5Y cells using GH or DRD1 
as read-out in the presence of LRRK2 pathological mutants (Figure 21–22).  
To date, the role of kinase activity in LRRK2 physio-pathological function is still 
controversial because different pathological or risk factor mutants exist with unchanged or 
reduced kinase activity (for review see Greggio et al. 2009, (141)) and because in different 
experimental models the kinase dead LRRK2 mutants behave as the pathological mutants 
(99). Under our experimental conditions, the LRRK2 D1994A mutant protein shows smaller 
but consistent effect on both DRD1 membrane level and secreted GH compared to 
pathological mutants despite the fact that LRRK2 D1994A has a robust reduction in kinase 
activity (75, 133). In agreement with this result, the LRRK2 inhibitor GSK2578215A reduces 
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but does not fully eliminate the LRRK2 G2019S effect either on DA or GH extracellular level. 
Taken together, these results seem to suggest that LRRK2 may primarily act as a regulatory 
scaffolding protein, where the LRRK2 kinase activity may further support this function. The 
absence of biological effect of LRRK2 lacking the kinase domain (LRRK2ΔKIN) on both GH and 
DRD1 readouts may be in part explained by a destabilization of the protein due to the large 
amino acid deletion. 
Interestingly, the LRRK2 biological effects, in all the tested experimental conditions, seem 
to be neuronal specific, since no increase in GH extracellular level or DRD1 membrane level 
was observed in HEK293 cell when mutant LRRK2 is present. Neuronal-specific mechanisms 
of vesicle trafficking are well described (126) and this aspect could explain at least partially 
the neuron specific toxicity of mutant LRRK2. This view is supported by experiments in vivo, 
showing that the LRRK2 effects on DRD1 localization in neuronal cells is observed in the 
striatum of G2019S transgenic mice. The transgene expression determines an increase of 
DRD1 in the plasma membrane fraction that correlates with a decrease in the vesicle 
fraction. This effect is possibly specific for this receptor since it is not detectable for NMDA-
NR1 or EGF receptor (EGF-R). It is generally accepted that membrane receptors show 
different turnover rate and different endocytic pathways. For instance, NMDARs are 
considered to be relatively stable once delivered to the cell surface of mature neurons, 
especially when compared with AMPARs that, even under basal conditions, cycle much 
more rapidly to and from the surface (142) whereas DRD1s internalize rapidly following 
agonist-induced activation (143). EGF-R is a member of tyrosine kinase receptors family, 
whereas DRD1 is a G protein coupled receptor. The confocal microscopy results suggest 
that LRRK2 is not involved in EGF-R trafficking after EGF stimulation, corroborating the 
hypothesis of a specific influence of LRRK2 in DRD1 trafficking.  
Taken together all these observations indicate that the LRRK2 protein does not seem to 
exert a general control in secretion but rather accurately modulates the vesicle turnover. 
The amount of secreted neurotransmitter or plasma membrane protein at steady state 
level is the sum of the transport reaching the cell surface from biosynthetic pathways, the 
leaving of the surface via the endocytic pathway, and the returning to plasma membrane 
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from the intracellular endosomal pools; consequently, a change in any of these parameters 
could be responsible for the differences that we observe in DA or GH release and DRD1 
membrane localization. 
For instance, LRRK2 has been implicated to different extents in vesicle trafficking either 
directly throughout endocytosis regulation (96, 97, 99) or indirectly throughout interaction 
with actin or tubulin (108, 144) that in turn may affect vesicle movement among the 
cytoskeleton. The dysregulation on vesicle trafficking may have important consequences 
on neuronal toxicity. It is believed that inter-related processes like oxidative stress, 
excitotoxicity, inflammation, mitochondrial dysfunction and altered proteolysis are 
involved in the cascade of events that will lead to DA neuron death (145).  
In this respect, the increase in neurotransmitter levels in the inter-synaptic space or the 
increase in membrane receptors in neuronal plasma membrane due to the expression of 
mutant LRRK2 could alter the normal neuronal physiology that in turn may lead to 
neuronal toxicity. For instance, a dysregulation in DA level has been extensively studied as 
prominent PD etiological factor for the neurotoxic properties of DA metabolites (146, 147). 
LRRK1 and LRRK2 have similar domain arrangements and are each other closest homologs. 
Leucine rich repeat kinase 1 and 2 are members of the ROCO family of multidomain 
proteins (148), characterized by the presence of a Ras of complex (ROC) proteins domain 
and a C-terminal of ROC domain (COR) which is unique to the ROCO proteins. Although, 
LRRK1 has been shown to interact with LRRK2 (113, 124), and it has been suggested that 
LRRK1 may therefore be involved in the same cellular processes as LRRK2, little is known 
about this. However, LRRK1 is not linked to PD, thus clues for the specificity of LRRK2 
function can be obtained from comparative studies with LRRK1.  
LRRK1 has previously been shown to translocate to EGF-R transporting endosomes upon 
treatment of HeLa cells with EGF (117), while nothing is known about possible role of 
LRRK2 in endosomal EGF-R trafficking. As consequence, EGFR trafficking is a good terms of 
comparison for a functional redundancy study between the two LRRK proteins. After 
demonstrating that EGF treatment induces the translocation to both EGF-R and LRRK1 to 
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endosomes in neuronal cells, I assessed that LRRK2 is not showing the same behavior. 
Moreover LRRK2 is not required for recruitment of LRRK1 to EGF-R transporting 
endosomes, since LRRK1 recruitment to endosomes was comparable in LRRK2 knockdown 
conditions compared to control. Farther LRRK2 seems to be not essential for EGF-R 
trafficking to endosomes in general, given that EGF-R internalization appeared normal in 
LRRK2 knockdown cell lines. Furthermore LRRK2 is not able to supply LRRK1 function in 
EGF-R trafficking in neuronal cells as LRRK2 is neither recruited to EGF-R positive 
endosomes or changing the distribution pattern in a LRRK1 knock-down background.  
Actually, EGF-R trafficking does not show any perturbation when LRRK1 is knocked down in 
the SH-SY5Y model used for this study. This result, contrasting with those obtained on Hela 
cells by Hanafusa et al (117), can be explained with the complexity of the receptors 
trafficking machinery involving many different proteins. Among those proteins, probably in 
neuronal cells, some may have functional redundancy with LRRK1. Taken together this 
observations display no possibilities for cross-talk between LRRK1 and LRRK2 in the EGF-R 
trafficking process in neuronal cells. Considering that EGF-R is a broadly expressed receptor 
outside the SNC, while DRD1 is specifically expressed in the PD degeneration interested 
areas, these results provide a clue on the possible mechanisms underlying the specific 
degeneration of the dopaminergic system of PD, despite LRRK2 is expressed not only 
through the brain but also in some peripheral districts.  
Recent literature supports the notion that LRRK1 and LRRK2 may play distinct biological 
functions. For instance, LRRK1 and LRRK1 containing mutations equivalent to those seen in 
LRRK2 PD do not exhibit the same level of toxicity as LRRK2, suggesting that there is a 
divergence in the function of these proteins (114). This is supported by genetic analyses 
that have excluded LRRK1 as being involved in PD (149, 150). Moreover is reported that 
LRRK2 overexpression in cells and in vivo impairs the activity of the ubiquitin-proteasome 
pathway, and that this accounts for the accumulation of diverse substrates with LRRK2 
overexpression but in the same study such abnormalities are not seen with overexpression 
of LRRK1 (151).  
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Therefore, despite the similarity of domain arrangement and catalytic activity, and the 
possibility of a dimerization, LRRK1 and LRRK2 seem to possess distinctive properties that 
may account for LRRK2 specific association with PD and this functional redundancy study 
supports this hypothesis too. Moreover the absence of functional redundancy between 
LRRK1 and LRRK2 in respect to EGF-R trafficking point to a specific LRRK2 function for the 
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ABBREVIATION LIST 
 
 3-MT - 3-methoxytyramine 
 AD – Autosomal Dominant 
 AIMs - Abnormal Involuntary Movements 
 AR – Autosomal Recessive 
 ArfGAP1 - ADP-ribosylation factor GTPase-activating protein 1 
 AUC – Area Under the Curve 
 CNS - central nervous system 
 COMT - catechyl-O-metyl-transferase  
 COR – Carboxy Terminal of Roc 
 DAR – DopAmine Receptors 
 DAT – Dopamine Transporter 
  DOPAC -  3,4-Dihydroxyphenylacetic acid 
 Dox – Doxycicline 
 EGF – Epidermal Growth Factor 
 EGFR - epidermal growth factor receptor 
 EGF-Rh – EGF Rhodamine (conjugated) 
 EM – Electron Microscopy 
 ER - endoplasmic reticulum 
 ERM - ezrin/radixin/moesin 
 GEFs - guanine nucleotide exchange factors  
 GH – Growth Hormone 
 GNEF: Guanine Nucleotide Exchange Factor  
 GPCRs - G protein-coupled receptors 
 GRKs - GPCR kinases  
  HVA - homovanillic acid  
 KD – Knock Down 
 KIN – kinase 
 LB – Lewy bodies 
 L-dopa -  Levodopa 
 LRR – Leucine Rich Repeat 
 LRRK1 - Leucine-Rich Repeat Kinase 1. 
 LRRK2 – Leucine Rich Repeat Kinase 2 
 LV – Lentiviral 
 MAO B - monoamine-oxidase B 
 mGH - murine growth hormone 
 MPTP - 1-methyl-4-phenyl-1, 2, 3, 6,-tetrahydropyridine 
 MS: Mass Spectrometry  
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 NR1 - NMDA-NR1 receptor 
 OE: OverExpression 
 P: Phosphorylation/Phosphate  
 PBS-T -  PBS 1x containing 0.1% Triton 
 PD - Parkinson Disease 
 PINK1 - PTEN-induced kinase 1 
 PVDF -  polyvinylidenedifluoride 
 RP recycling Pool 
 RRP - Readily Releasable Pool  
 SNARE - Soluble N-ethylmaleimide-sensitive fusion protein-Attachment protein Receptor 
 SNCA – Alpha Synuclein  
 SNpc – Substantia Nigra Pars Compacta 
 SV - Synaptic Vesicle  
 TRAP1 - TNF receptor-associated protein 1 
 UCHL-1 - Ubiquitin carboxyl-terminal esterase L1 
 WB: Western Blot 
 WT – Wild Type 
 Y2H: Yeast Two Hybrid 
 α-Syn – Alpha Synuclein 
 
